var title_f7_14_7392="Intraperitoneal catheter";
var content_f7_14_7392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Intraperitoneal catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joan L Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7392=[""].join("\n");
var outline_f7_14_7392=null;
var title_f7_14_7393="CCK releasing factor regulation";
var content_f7_14_7393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Model for regulation of CCK release by an intraluminal releasing factor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 308px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE0AewDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorA1rxj4e0W4+zajq9pHeYyLVH8yc/SJcufwFAG/RXEy+P/Nz/AGV4a1+9HaR4EtF/ETuj/wDjtV38XeJ3z5HhawT0+06uU/8AQIXqXOK3Y7M76ivPv+Ev8VIcy+GdHK/9MtakY/kbZR+tPT4g3cJxqPhTVUXvJaTQXCj6jer/AJKaXtYdwszvqK4FPiz4WkuZbWJ9Xe+iCmW2XR7vzI89N37vAHvnB7ZqY/E7Qx1tNd/8FNx/8TT54rqKx3FFcQvxR8LnHmTarCT183R7xAD6bjFj9a19D8aeGtcultdK1uwuLtgSLYShZiB38s4bt6U1JPYDoKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc94m8VWuizxWMEE2pa1cLug062wZGGcb3J4jQHq7EDsMnigDflkSKN5JXVI0BZmY4CgdST2FcTP47Opu0PgvTm1nBIN/I5hsUPtLgmT/ALZqw9SKr/8ACM3uvypdeOLmO8UENHpFvkWUJB43A8zt05f5c8hVrqBGqIFRQqqMAAYAFRKXYpI5GbQNT1f5vFOu3V0jdbHTy1nbD2O0+Y4/3nIOPujkVo6Voum6NbfZ9JsLWyh7pbxKgPucDk+5raZahdaxk29xoqOtQOtXHXioHFYyRSKUi1WkWr0i1WkWsWhnM+IvD9rq/lysWttQhybe9h+WWE+x7r6qcg9xVTw3fz6lpO6+REv7eV7a5WP7vmIxUlfZsBh7MK6aUcVR8mONpDGiIZG3OVGNxwBk+pwB+VZy2sCKUq1kaxp1vqNuI7lTlSHjkRirxMOjIw5Vh2IrbmFU5RXO7p3RR0fw48a3Ut8nh3xRKr6kVLWV9tCLfIOSpA4EqjkgcMPmHcD0qvn7VLBNQtTCzvFIjCSGeM4eGRTlZEPZgef/AK1eq/DXxNL4k0Am/VI9XsZDa3yKMDzAAQ6j+66lWHpux1Br1cJifaq0t0ZSjY6yiiiuwgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApsjpGheRlRByWY4Ap1cN8crW4vfhJ4otrOCW4uJLQqkUSF3Y5HAA5NAHawXENwCYJo5QOCUYNj8qkrxDVfD+s/Dvw1ZWulXAitb3US2p6h4d0JUmghEJ8sCAGTOZBgvjgNjjvmat4l+JyQaGZYdUttTfToZbeC20xZIry6MxDpdNg+SPKCMQCuNzHPAAAPoBnRXVWZQz8KCeT9KdXgtrP4l1L47aN/bI1hrex1fUBHC2n7bOC2+yyLBIs4X5i4POWPPGBgZ96oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKw/EnifTfD/kx3bSzX1xn7PY2qGW4nx12oOcDuxwo7kVn+MvEd1ZXVvovh2KG48QXa+YomyYrWHODPLjsDwq5BY8DgEhnhrw7a6KJp98l5ql1g3eoXGGmuGHTJ7KOyDCjsKlysNK5XW68Zaz8yrYeG7Q9FZftl2R74IiQ/8AfwU4eEGn51PxH4kvXPUjUGtQfwtxGBXTKKlVaNWOxy3/AAgukdRProfvINdvg5+r+duP51Qtvh5BpVzd3XhvWtY0u7uiHmd5heCVgMLvM4dmAAxww+td4FpStOwHFWetatpOp2+m+LIbd47p/KtdVs1ZYZXPSOSMkmJz25ZWPGQSAepZasstRMKloaKrConWrLioXFZtAVWFQOKsyCoJBxWTQ0VZBVWQVckFVpBWMkUUpBVOUVekFVJhyawkBRmFUpRyavyjiqUo5rCZRSbhjVzwJctpnxKtAhxDrFrJayr/AHpYgZI2/BfOH4j0qpJ96pPDcTXXxH8LxRglrZ7m+fHZFt3hyf8AgVwlVhG1WVhT2PcKKKK94wCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkyM4yMnnFLXI/EW0nhsrPxFpsTS6joUhuhGg+ae3IxPCPUsnIH99EoA66iobG7gv7K3u7OVZra4jWWKRTkOjDII9iCKmoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArO8R6vBoOh3uqXYZoraMvsQZaRuioo7sxIUD1IqzfX1pp8Bmv7qC2hHWSaQIo/E159ruvaX4w8T6HpWi6ha6jY2Uj6leyWsqyxh4sLDGzLkZ3vvx1zDSbsrgaPg7SrmytJ77WCj67qTi4vnU5Ctj5YlP9yNcKPXBPVjXSoOagSp4+tZJ3LJ1FTKKhWplrRCZIBRigUuaoQxhXPeL/FGkeE7G3u9euXt4LicW0RSCSZnkKswULGrHojHp2roW6VwnxT8L3niuDw5b2VxPbLaavHdzz283lSxxCKVSUbB+bLr+tJjNzQNd03xJpMWp6LdLdWUhZVcKykEHBBVgCpBHQgGrb14h8TvhPql3p1hpnhK0tbiCCOeb7dqF/L9pW7eQSNL/AHSzFcbsZ56gDmW2+GGpweJTrNqEs9Qn1PV5Zbtbg7lt7iOXyPlBxw7I2B0IzWckhnsclQPXiukfDDVBoNlp2o6RpdvbpqtlPcwRXks63CRIyzStv+XLk52gAkcMTgVUk+GviiHxF4o1CNo7mS9ju1ikk1AxpcpKw2ROqRiQBVz/AMtMAgYwM1m0u4Htr1VkrxCH4Za9H4Saxl0+086PU5ry2to7pXtokkgRQpSRCGAYP/dZT8ynJr2TTY7mLSbKO/8AJ+2JAizeTny94Ubtueduc4z2rCaS6lJiyVTm6mrklU5utc8hlOTpVKWq2qavdWd28S6JqV1DgFZ7cwlWPcYMgYY+mKyZtY1a4+Wx8O3KN2e+uIok/wDHGdv/AB2spRbHct6peW9hbSXN3II4YxlmPPsAB1JJ4AHJNd38KvDd1YxXWu61AYNT1BVSO3cfNa26klUP+2SSze5C/wAOa4j4aaVPefE1ZfEr295LBp7XNnBHGRDbSCRVLgMSWfDDDnGMnAFe713YOgor2m7ZnOXQKKKK7yAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4vwQDoGs6n4Sk+W3gzf6X6G1kb5ox/1ykJX2Vo67SuW8fWk6WVrrunRNLqOiyG6WNPvTwkYmhHqWTJA/vqh7V0Wn3lvqNjb3tjMs9rcRrNFKhyHRhkEexBoAnooooAKKKKACiiigAooooAKKKKACquqahZ6Vp899qVzDa2cC75ZpnCqg9yacL21N8bIXMBvRH5pt/MHmBM43beuMkDNcr44SO58R+ELO92mxkvZZTG4+WSaOB2iU+uCGcD1jB7UAZt/8W9Ct7+2sraw127urkEwILBrYTYGTsa48tW454PTnpSP428SXXFh4as7VT/Hf6j8w/wCARI4P/fYrA+NgUeD9Tn4FxbR/aLZu6zoQYyPfdgfjituI8VxTxEk7ItRQxrzxle/6/XdOsFP8Nhp2WH/A5XcH/vgVGfD8t3/yFfEHiG/yckG+Nup+qwCMEe2MVDeeKNC06URXusWEM3QRNOvmE+gXOSfoKkg8Src/8grR9d1H0aHT5I0b6SShEP4NSU6kh2SLNl4N8N20/npolg9xjHnzQiWXH++2W/WuliCoqqgCqBgAcACufiPi+7/49PDdrZD11PUlVgP92FZQT7bh9aq6gPFOla74dj1DUtJe3v7t4Zbe1snBVFglkz5jSHJ3IgwFHU1qoS3Yro7NDUyGqyGplNOLAtKalU1WRqlVq1TBosBqUtUAal3VVxD2NRMaC1Rs1S2MbIagc09jULms5MCOQ1A54qRzULmsmxohkNVZTViQ1VkNYyKMDStRnvdW1+3lCeTY3aW8WBg828UhzzzzJ7VbmPJrE8DN9p0u81Ifd1G+nuUPrHu2Rt+MaIfxrZlNZVN7AitKeKpS1bmPFYutagthCm2J7i7mcQ21rHzJPKeiKP5noACTwDXO05OyGb3wriN145168A/d2VnBaBv+mjs0jr+CiI/8Cr1iua+Hvhx/DPhuK1upEm1Gd2ur2VPuvO/3tv8AsqAEX/ZUV0te3Sh7OCj2MW7u4UUUVoIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuK8Gf8AFP8AiDU/Ckny2y51HS/T7O7fvIh/1zkJHsskYrta8g/aF1zXfDFhpniHQtC+2nS5DL9uSYnyAwKyJLEFyYmQg7g3DKpIGASAev0VyPwi1W51z4ZeGtSv5pJ7u4so2mlkxudwMMTj1INddQAUUUUAFFcP8WviRpPw38PNfaiwmvpQVs7JWw87/wBFHGW7e5IBuyeM9L0Lwjpeq+MtUsdNmuLSOWUO23dIUBYRpkseSeBk0AdXTZZEijaSV1SNRlmY4AHqTXkf/CzvEni4mL4Y+Eri4tm4Gs6zm2tB/tKv35B9MH2pYvhJf+JJFufih4ovtd53f2XaMbWxQ9htXBfHqcH1oA0Ne+M/hy1vm0zw1FeeK9Y6C10aLzlX3aQfKB7gnHpWb/ZPxS8bc63qlr4I0lutppZE96w9Gm6IfdPyr07QdC0rw/YLZaHp1rp9qvPlW8QQE+px1Puea0aAON8C/DXw14Lnlu9ItJJdUmUrNqN3KZriUHGcsemcDIAA4rf8R6JaeINNayvvMUB1limhfZLBIpysiN2YH/A5BIrTooA831P4Xvrj248QeK9Zu4LaRZYooUggDMpyrSFU+Yg4PGBkA4zWpD8MvCwA+22M+ptyD/aV3NdKf+AOxXHsABXaUVKil0Ao6Vo+maRF5Wk6dZWMeMbLaBYhj6KBV6iiqAK4nxxj/hLvCG7p5l1jP97yf543frXbVyvxD0i81DTLS+0hPM1XSrgXlvCW2icbWSSLPQbkdwCeA209qUldAiwpqZWrG0PVrTWdPS8sZC0bEqyspV43BwyOp5Vgcgg8g1pq1cqZoWlapFbFVlanhq0TEWQ9G+oA1G6nzDJS9MLUwtTGak5AOZqhdqGaua8Za3LptpFZ6Zsk1zUGMFjE3OGxzKw/uIPmY+wHUiouBo6Tqtvq9ibu03+T5ssILjBJjkaMkexKEj2xU7mqWh6bDoui2Wm2xZobWJYwzHLOQOWPqSckn1Jqy7VnJjRHIa4H4ieKrSxT+w4L6ODU74eU0hbAtI2HzSsexC52jqWx2yRu32rXWo6k+i+Fo47zVlIE8rcwWAP8UxH8XcRg7m9hyO78I+HLXwzpZtbZnnnlczXV1LjzLmU/ediPyAHAAAGABVU6TlqxSlY8usvEOhWdjbWWntcGCCNYooobSZyEUYAACE8AUra/BJnybDXpgOpi0S8kA+pWI17XRVPCRe7ZPOzxNJNY1NxBo3h7VHnfpJf272UKD+87SKDj2VS3tXb+CvAsWi3f9raxOmpa+ylRPs2x2ynqkKknaPVidzdzjAHa0VpToQp6rcTk2FFFFbCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAorD8dapcaH4J8Q6tZBDdWGnXF1EJBld6RMy5HcZArA8VeKtU0/wn4bm0uOzbWdduLayhe5DeRE8sZdnYKckAI2BkZOOaAO7orxDxt468a+FoNOsr2fR5L6S+ngkutPspLsmFLfzQxtw+5G65G4gL83SsmX4peNbiw8LNbwQrJqkF3ceZaaRLetNFHIixSCFJNyBlbJyxwceuKAPoWiq+nmc2Fsbtle58pfNZUKAtgZIUkkc54zxVigAooooAKbIiSxtHIqujAqysMgg9QRTqKAOW1iWDwF4Nkk0HRhLY2JaQ2kD7BGjMWdl4PALE46AZxwMVH4T8d6V4g8Jza8XFpDbBvtUbtkwleefXIwR659a6t0WRGSRQyMCGVhkEehr5G+IFlF4c8YaxoGj6l5ekXMsfnRgkpHzuCvjrsJPTP55rGpNw16HuZTgaOYRlRek1Z3126r/ACPoX4c+On8bm9mt9IltLG3OwXEkobzH/ugY7Dk88ZHrV74i+LP+EP8ADk2oRabfapeH5Lezs4WkaV+2doO1R3Y/qcA6HhHRrHQPDtjp+lbWtY4wRIP+WpPJcnuT1rYrSN7anl4uVKVaToRtHov+HPzq8b23xA8aeIbjWde0LXJrqY4VRYShIk7Ig28KPT6k5JJr6A/Z20fQNTlDeLfCesHxgg3G+1yGWdJgOcxs67UI9CM+hPb6VoqjnADAwOleKeP9Chg+KFtLFfawqzaTfam8K6lOsRmhMWz5A4AX5jlRwc17XTGjjZgzIpYArkjnB6igDxmTx74ts/DvhS5nOm3N54o02I2JjtWRI72V4iqsN5yoilZjyP8AUt0zis/Tvit4hl8Zatpf2jQJ1gudWt0t2SSGS1W1DmKaeTcVEbFQhOB14PUD2G88Oabe65puq3MUj3OmhhaJ5rCKJiCpcRg7d21iMkZANS6HoWn6GLwadD5f2u6lvJSWLFpJXLucnoCxJx0FAHiX/CzdUvvD+mzzyWs+p22tx283lRbIk3Wc0o2vFO6SjK/3umMqDg11vwo8Y+Jdc1iGz8THS3W80Gz1u3ayieMxiYspRtzHJ+XPGMZr00W0AQIIIggO4LsGAfX609Io0IKRopChAQoGFHQfSgB9FFFABRRRQAUUUUAcj4i8GJd6jJq2gXh0fWpAPNmSPzIbrAwBPFkb8DgMCrAcbscVitq2uaOCviXw/c+WvW90kG8hb3MajzV+mxgP7x616RRUygpbjTscBp3i7w/qEphtNZsXuB96AzBZV+qHDD8RW8HrU1PSdO1aLytU0+0vYx/BcwrIPyYGsL/hXPgj/oTfDf8A4K4P/iaj2XmPmLQeoH1C1Ryr3MCsOCDIAR+tM/4Vz4I/6E3w3/4K4P8A4mrEfgfwnGgSPwvoSIOAq6fEAP8Ax2j2fmFyudTs/wDn7t/+/q/41n6r4n0TS4g+oatZQBuEVpl3OfRVHLH2AJrb/wCEK8Lf9C1on/gBF/8AE1c0zw/o2lSmXS9I0+ylIwXt7ZIyR9VAo9l5hzHFxXHiLxHhNAsW0mwYc6nqkJDkf9MrckMT7ybB7NUlh8KdMtL6e/8A7a8QS6ncKFnvHvB5kgHbhQAv+yAAPSvQ6KtQSFc4s+AUB/deJPEcXr/pMb5/77jOPwpp+HdpP8uoa54gvYD96F7wRK3sTEqMR7Zq14z+IfhjwVdWtv4n1J7B7pS0LNazOj4PI3qhXI7gnPI9RWh4S8V6L4usZL3w7eG9tEbYZhDIiFu4BZQDjvjOO9HKuwXZoaRpdho1hFY6TZwWdpH92KBAij1OB3Pc96uUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorntV8Y6Np989gLiS91JfvWVhC9zMnpvVAdg92wPegDV1nTbbWNIvtMv0L2d7BJbTIGKlkdSrDI5HBPNcnbfC3wzFpVzpsseo3dlP5f7u61GeXyjGco0ZZ8xsPVcGtD/hIdbmUtaeD9SVcZU3d1bRbvwWRyPxAP0pD4i1yEA3Xg7U3GMk2l1bS459GkQn8AfxoAj0T4e+HNFn0+fT7ORbiyuZbtJpLiSSR5pIzG7yMxJclSRznHaptB8C6DoN/b3el2skMlsLhYE85ikSzuryKqk4CllBA7c461R1T4kaHpmn3U1/8AatPu4oXkjttSt5LTzmVSQiSOoRicY+Unk1seCvFmj+M9Ag1jw/dC4tJeCDw8bd0df4WHp+IyCDQBu0UUUAFFFFABRRRQByfxM8Unwp4YmurdDLqEv7q1jC7vnI+8R6Dr+Q715l4L+FP9teBdQvtd3DXNVHn20spO6H+JWb3cnLexHeveaKzlTUndnpYfMp4Wj7OgrSbTcurtsvT8zyL4FeI71Yrjwnr8csV9pxZbcyL1RThkz3Knp7fSvXaKKqMeVWOfG4iOJrOtGPLfdefX7woooqjlCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwfG/hPSfGnh640bXrcTWswyrDh4n7Oh7MP/rHIJFcz4b8Aah4Q8Pada+FtaaG5tIFilt7oNNZXLADLbCd0TNjOUYDJJKtXolFAHMaH4sS51JdI1yzfR9dKlltpXDx3AHVoJeBIPUcMO6iunrO1/RbDX9Nex1W3We3YhhyVaNx910YcqwPIYEEVzumapfeGtTt9F8T3JurO5cR6bq7gDzG7QT44Ev91uA/s3BAOzooooAKKKKACiiigAooooAKyfEuvWfh3T4rzUBKYZLmG1Xyl3HfLIsa9xxlhmtauT+Jvh7UPEvhgWWkS2sV9HeW13G11u8smKVZMNtGeduOKAOjuL+ztpfLubu3hk8tptskgU7FxubBP3RkZPQZqr/wkGjeeIf7X07ziu/Z9pTdt2b84z02ENn056V5r4m8GeO/EM0F9cX3hm31AWV7pkqxxztF9nnWPDLk58wMjdeMY61Qi+CxlvYLnUV0i6dL7Sp3aSIuzQWtqsMkeSvRmUkDoR1oA9cGtaUfseNTsT9t/wCPXE6fv/8Ac5+b8M0tlrOl31ybey1KyubgKXMcM6uwUNtJwDnAYEZ9RivDF+A9+LvR3N7pckNtujkSTzh5CC9luFMOxk52yBcHABXINdZ4J+Fr+G9d8Paov9nLdWf9p/b5oUIkuftEweHLYy2xRjnp2oA9WooooAKiuriG0tpbm6ljht4UMkkkjBVRQMkknoAKlrhbxP8AhOPEc1i3zeGNIm2XS/w392vPlH1jjOCw6M+AeFYEAWFtU8cnzlku9H8Kt/q/LJiu9RX+9uHzQxHtjEjDnKjg9ZpGlWGjWKWWk2cFnapyIoUCjPcnHUnuTyau0UAFFFFAGJ4x8N2vizQ5tI1G4vIrKfiZbWXy2kX+6WxnHqBjP0rnfh78KfDfgC/uLvw4L+KS4TZKsl0zo4HTK9CR2PUc+prvaKAMbxH4gttEiTzVMs78pEpxkepPYVz9n4/jedVu7IxxE4Lo+4r+GOaxfiGsg8RuXztMaFM+mP8AHNczXxmPznFU8TKFN2UXa1t/+HPpsHllCdCMpq7aPdoZUmiSWJg8bgMrDoQe9PrC8ELIvhizEuc4Yrn+7uOK3a+tw9V1aUajVrpP7z52tD2dSUF0bQUUUVsZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVPWNMs9Z0u507UoFns7lCkkbZGR9RyD3BHIIyKuUUAcl4P1G8s9RuPC+vTNPqNnH51pdv1vrXOA5/6aIcK/uVbgOAOtrmPHumXNzp8Gq6Sm7WdIk+12qjrMAMSQH2kTK+zbT/CK3NI1G21fSrPUbCQS2l3Ck8T/AN5WAIP5GgC3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfj3V7nS9EWHSiv9tajKtjp4YZAmfPzkd1RQ8h9kNafh3R7XQNEs9LsAwt7aMICxyznqzMe7MSST3JNc/Zf8Tz4kXt2TustAhFlD6G6mCvKfcrH5Kj03uK7GgAooooAKKKKACiiigDM1zRbTWYFjulYOn3JE4Zf/rVhWfgOyhnD3FxLOgORHgKD9e/8q7CiuOtl+GrT9pUgm/6+86aeMrUo8kJNIaiqiKiKFVRgADAAp1FFdhzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFch4GH9lat4h8OE4jtLkX1ovpbXJZwB7CVZ1HoFH0rr65HWf8AQPiR4du1ICajbXOmyDP3nUCeP8ljn/76oA66iiigAooooAKKKKACiiigAooooAKKKxbnxX4dtdVGl3OvaTDqZIUWkl5GsxJ6DYTn9KANqob66hsbK4u7lwkEEbSyMf4VUZJ/IVNXI/FM+f4SfS1JDaxcwaZgd0mkVZfyi8w/hQBL8M7Sa38HWVzepsv9SL6ldA9RJOxkKn/dDBfoorqap6nqWn6PZNdapeWthZpgGW4lWKNf+BMQBTdH1jTdbtPtWjajZ6hbZ2+baTrKmfTcpIzQBeooooAKKxbLxX4dvtTbTbHXtJudRUkG1hvI3lBHX5Ac8fStqgAoorL1vxDougrG2uavp2mrJwhvLlIQ303EZoA1KKitLmC8to7i0nint5BlJYnDqw9QRwalNABmikrI1/WotHNn5mD50oRh3CY5b8Dis6tWFGDnN2SLp05VJcsVdmxRRRWhAUVkax4m0HRJ44Na1vS9Pmk5SO7u44mb6BiM1qxSJLGkkTq8bgMrKchgehB7igB1FFV9QvrTTbSS61G6gtLWPl5p5BGi/VjwKALFFZ2i65pOuwPPomqWOpQodrSWdwkyqfQlSQDWjQAUUViy+K/DsWr/ANlS69pKapu2fY2vIxNu9Nmd2fwoA2qKKKACisrW/EeiaCYhrms6bppl+59sukh3/TcRmtG2uIbqCOe1ljmhkG5JI2DKw9QRwaAJKKKiu7mCztpLi7nigt4xl5ZXCKo9STwKAJaKy9E8RaLrwkOh6xp2pCP75s7pJtv12k4rUoAKKKxrfxX4eudVOmW2vaTNqQJBtI7yNpgR1GwHP6UAbNFFFABRWfrWt6Vodus+t6nY6dAxwJLu4SFSfQFiBU+nX9nqdnHd6bd295aycpNbyCRG+jAkGgCzRRRQAUUUUAFFFFABRRRQAUUUUAFcn8Q/3MXh695BtdbtMEDp5rm3/lMR+NdZXKfE8f8AFJFucpf2EikHoy3kJB/MCgDq6KKKACiiigAooooAKKKKACiiigDgviXrd35tr4b0adre9vo2nurmM4e1tVIBKns7sdint87Dla8l8QaVYWmnvZW9pClpggxbQQ3qTnqT3J5Nd/prHU7vxD4gfn7devbW59Le3JiQD2LrK/8A20rjPFX8dexlsEte55+Nk7Gz8AvGk326Xwhqs7y7EabTZZGLNsX78JJ5O3IK/wCzkfw13vja8gi8V+GRezLFZ6el7rVwzdFSGHyix9h9pz+HtXy2mqyaBr1jrcIYyabcpdYXqyA/Ov8AwJC6/jXunxCmTXPiNZaLAwkgurG1ErKePs7Syzyj6N9liQ+0o9eMMywyoV7R2eostxLr0fe3Whk6iLnX5h4i12JhdTDdZWkvIsYTjaoHQSEYLt1ycdAK4afWb7wn4ii1zQ/lu4yPPhB2rdxDrG/rxnBP3TyO+fVvE/Rv8+leO+Kv9Z/n2r1MFQhOn7OS0Zx4+tOm/aReqPrDw/q9pr2iWOq6c/mWl5Cs0Z74YZwfQjoR2Irz74jalNr2rz+G7WVo9KskV9VeNirTO4yltkdF2/O/qGQdGauf/Zu8RRweF/EGl3su2HSJTeISfuQShnP5Okp/EVo6FBMvhWG9vU26hqhbUroHqHmJfaf91SqfRBXiRoclZ05dGeqqyqUlUj1R534tsbX7J5CwRpFFzEsY2eWRkgrj7pB6EdK9S+BPje48SaTdaRrMxl1nS9oMzfeuYGzskP8AtDBVvcA/xV5t4t+7L+P9a534aa03h/4maFeb9kFzN/Z1x2BSYhVz9JBGfwNezi8NGrhnNLWP5HlUsS6WKUG9Jfn0PqDxrr6+G/D898sQuLtmWC0t848+dztRM9hk5J7KCe1eManpbWvnXmoyi91q4+a6vXX5nb+6v92MdFUcAe+SfQvFjHVfH9lZnm10aya+cdjPMWjiP1VEn/77BrkfFfR/r/jXm5fBc3Mz0sW/dscV4F8YP4E8XRhpNnh2+lWO9g6JCzHAnUfwkHG7HVcnkgV9S18WeJI1lmljkAZHBVge4Ne/+CPGsx+BA1tybjU9NtJbUq3WW4iJjQH3chD/AMCrfNsMqco1YrR7+pyZXiXU5qUt47ehdn8fXC3F5bWwsrhraeS3aVNxG5GKkEZ6gjn3rz7x/wCLvsGn3Op6pcBrjYVgj/vN2VR6Z61yni+1l0TSILWKeTz4YwJJlYhpHOC7k+rMST9a8Y124muZC9xLJK/TdIxY/rXzNThyriJKVau3Tvflt+F/1PdWe06F6dKklO29/wCvuPtr4IePV+IHgiC/n2Lqts32a+jXgeYADvA/usCD7HI7VsfEHxBPoWjxR6aEfWNQmFpYo4yocglpGHdUUM59cY7ivlr9knxG+lfEqXSJJMWusWzJtJ486MF0P/fPmD8a+g9Wf+1viDqdw3zW+iWyWMQ7CeULLMfrs+zj8W9a9Pk9/lOVSvG559qmlQWEU+S9zdTkvc3U+GluHPVnPf6dAOAAABVb4Q+MX8K+LIdCupcaBqUoiiRj8tpcN93b6I5+Ur0DFSMZbOx4p/i/z6V4/wCIYzK8qI5R+qOOqsMEMPcHBr6GGFjXoOFtenqeFiMVLD1YzvpfX0PtqR0ijaSRlRFBZmY4AA6kmvCdVuJPF8//AAkWpbmsWJOk2j/chh52zFf+ejj5s/wqQox82em1bxC/iv4S6AI223XifyLGYJxt3AtdAfSOOcVX8SoscZSNVVFGFVRgAc8AV4uDgnO76Hs15e5oeSavf3ug65DrWhyC31SA8N/DMvOY5B/Eh6e3UYIBr6b8G+IbXxV4Y0/WrEFYbuPcY2OTG4JV0PurBlP0r5e8W/eP1/xr0H9mLWSs/iDw/K/yKU1C3U9t3ySge2VQ/VzXo5phl7KNeK16nmYDEv28qEtt0dz8TNYupru38MaRO9vNcxG5v7mJtrwWu7aFUjo8jZUHsFcjkCvJvEel2EGnNYxWkC2eMeSEG09Oo7n3rv8AR2/tFda8QP8AM2q3shhPpbRHyogPYhC/1kNcZ4p6P/n0rPLYJavqdOOk7HRfAHxtcXM8/hPWJ5J5reMz6fPKxZnhBAaJieSUJGD1Kn/ZyfS/HXiA+HNAe5t4ln1CeRbWxgY4Es78KD6KOWY9lVjXyXp2sN4c8T6XriEj+z7pJpMHBMR+WUfjGz19I+I5Dq3xCjjB3WmiWPncdDcXBZQfqscbfhNWGYYVUcRyx2eoZdinXoXlutDzzU9KFl5txdym91W4+a7vpQPMmbj/AL5UdFQcAcCsb4ceMH8E+L4bSSTZ4c1GYRXEP8FvK+Asyj+EFiA3bB3dRz1niv8AirxzxJCk7zQyDKSKVYexFerRwsK9F02vQ4MViZYeoqi76+h9r14d4ivD41u5NVuz5ug28rJpdq2DHLtJU3TD+IsQdmeigEcsca+n+K7rXPgTY3MUzf2zqCJoxkB+cXDSfZ3k+o+aT6Cna3aQ2FhDZ2qCO3t4xFGg6KqrgD8hXh4Wn+897oezWl7l11PJPEU1zpuqQarpE32PVbZsw3KDkdflb+8h6FTwRX0f8PPFMHjLwnZaxCghlkBjuIM58mZTh0+mRwe4IPevm7xd/F9f8a6n9m3XVsPEOvaPcSBLa5thqSbjhVeMhJD+KtF/3wa9TMsMnRVaK1W55eCxLjiHQez29Tv/AIk6nPrOpv4YsZpIbKCJZ9VmiYqzBv8AV26sORuALNjnbgfx15V4r06zWx+yJawpbRgBI0QKqY6bQOmO2K9B8Pq0/hxtYnUrda3K+pybuoWT/VKf92IRr/wGuJ8WdJKzy2mlutzox8nbQ7/4C+N7jXrC60HWZ2n1XTFVo55Dl7m3PCsx7sp+Vj3+Unlq9E8Ua1b+HfD99q14GaG1jL7E+9I3RUX/AGmYhR7kV8n+A9ZPh74iaDqQbbEbkWc/PBimIQ59gxR/+AV9D+PnOpeKPD+jdYIBLq9yvY+VhIVP/A5N494q48fhlQxDhHZ6o1y/EvEUFKW60Z53qVjdSSyatr7Lca7cLmR85W2XnEMX91F6ccscseTXIaL4pn8A+KxqloGGmzOBqVqg+WaPPMgX/noo5B6kAr349G8U9H/H+tePeJRm4Oen/wCuvXw2HhVpOm1oedjcROjJVIvVH2PbzRXNvFPbyLJDKodHU5DKRkEH0IqSvMP2ddabU/hzFZTPvn0id7A56+WuGi/KN0X/AICa9Pr5ucHCTi90e7CanFSWzCiiipKCiiigAooooAKKKKACuU+Jx/4pPaAS0moafGo9Wa8hUfqRXV1yfxE/ew+H7Tn/AEnW7Pj18p/P/wDaOfwoA6yiiigAooooAKKKKACiiigArP8AEOoDSdA1PUmxts7aW4OenyIW/pWhXK/FUbvhz4hh/wCfi0e2+vmfJj6fNQBz+laedK8FaLYtnzILKJJCerPsG4n3Jyfxrz7xV/HXrXiyaO3t5pp3WOGNS7uxwFUDJJPpXyz4j+MWiXOoSQ2tpeSWwbaLjAG4eoUnOPrg17GEqwpWc3Y4MVTlNNRVynqqhmlVhkHIIr0/4F37+JPF13fzESNo2g2WnFj13sq7j9f3J/M+teWT3MV5CtxbuHhlG5WHcGvUv2UbTytI8ZXO0jzdRWPPrtUt/wCz/rXXnCUlTmjzMlbU6kWdv4n6N/n0rx3xV/rP8+1dp8YfHuleEHhgvFluL2cb0t4sZC9NzE9BkEe+PY15HB4zsPE8jpBHLb3Cjd5cmPmHHII61eArU1NQb1NMypTdNyS0NnwbqLWurarpobC69p/9k4zgl5biGNcf8Bkk/OvpPxKoVGVQAoGAB2618yeCbT7X8T/CChdxTUlk644VGb/2Wvo74g6paaLpN5qOpTCG0t0LSORn2AA7kkgAeprkxkVHFt97HRl8nLCRXa55b4t+7L+P9a8t1mSSG3lmgbbPF+9jb0dfmU/mBVrUvi3pGqXTRfY7uCFiQJX2nHuQD/LNQX+2SJsEMrDgg9RXq4WpTr0pRi7nk4+E6VaMmj6d8L3SavL4m12PJjvr5UhzziOO3jTH/ffmH8a5zxX0f6/41c+BquPgp4fkmYPNKs8jtjGSZ5P5DA/CvKviL8XtEsNbudNtYLi+aBykssRAQMDyAT1x+X1rwcJUjT1k7H0OIhKatEx9f/4+mrqPhXqBn0O58NliVuPEVlc7D/dEbzEfTNicjp19a4Y6xaa5bre2LMYm4KsMMp9D71v/AAUMj/FWOBRmIWb3L84wUDIp9/8AXMPxr18z5amFUl3TPDy28MZKL8zc+Kf/AC1/z6V4PqvU17d8Zr+3022lnum2qTtUDqx44Hvwa+fp9Yhu5Nuxkz0Jrz1VhGCi3qd06M5VnNLQ2fhxqTaP8Q/DV+rbRBqMBc/7BcB//HSRX2d4ZHnaFqGonltR1O8uc46p5xSP/wAhpHXwa0jQsJIzh0O5T7jkV95+DPm+GPheU/en0y3nb/eeNXP6sa4LfvT0ofAcb4p/i/z6V5HrP/Hy9bHxB+LOi2Gs3GnWsM960LFJZYiAgYdQCeuMY9K5hNWtdat/tlkzGNjghhhlPHBr6LAVqcrwT1Pn80pTUVJrQ9U+BF8dTOm6WzZj0NtRn2n+FpTAUP0xNcfrXd+Kekn4/wBa89/Zjt1Ot+NZyfmWGyUf8C87P/oArb+MHjXS/B9sjagXluZyRDbxYLvjqTnoBkc/zryNKVed9k2exBupQhbeyOD8W/eP1/xrP8A+ID4X8XvqSttP9l30ZP8AuwNOB/31Ao+uKwo/HWn+JrhoIoZba45ZUkwQw56Ed/aqs8ck2r6TDE2GmvoYDzjKyPsYfiGI/GvXrShXwUnF3Vvy1PFhGVLHx5lb/gn1dFpg0XwxpemKMCztIrfH+6ir/SvNfFPR/wDPpXqPjzU7TRtKu9Q1GZYbS3QvI57Dj8z2x618xaj8YdG1K9MX2O8gt2bAmface5UHgfTNeXg6sKdud2PZxVOU0+VXKeqoJEljcZVgVP0Ne9/Be6n1fwA2uXgb7TqEqhie/kQx25x7boWP4mvBb1lcF0YMrAEEcgivov4RwLb/AAf8PKmMNFJLwMcvK7H9WrszdK9OXr+h5uSt/vF/XUxfFf8AFXj+uf8AH01avj74w6HbazcWFnBc3ohcxyTxlQm4HkLn7316elc42q2uswLe2LFoX4wwwVPcEetb5fWhK8E9TPNaclHma0PQ/gdfG+vbHQHJZbLUrnWAvYJ9mWIfh5kxP1x3r0/xV0f8a8p/Zvtw3xC1y5J5j0pYwMf3pgSf/HB+Q9K6n4y+O9K8GxxJf+ZNeXGTFbQ43EDgsc9B/kd68qfLSxM77XPWo3qYaFuxw/i7+L6/41xsF9dafq9s1iWE92sumgr1H2iJ4QfwZ1b/AIDUsXjrT/FDvFDFLbXIywjlwdw56Efyq34WgFz478LxFS3/ABNbV8Dr8sqt/wCy/lmvXqShVwcnF3VmeLyyp46Cas7o+m9ehjt7ZYYECRRqERR0UAYAryTxZ0kr0v4la7YeG9FudT1WbyraEc4GWYngKo7kn/OK+bbn4taRrF55DWl1aRyHasshUgem7B4/WvNwdaFNpTdj2MZTlOL5Vcoa0rPaXAjJV9p2sOoPY/nX0/4a1EeIdX1nXQQUaysLVAOi5g+0nH1+1L78D2r5mv8A+Kvdv2eZ/tXwq+0Eks1wYTn/AKYwxQD9IhW+cR9+nL1/Q4ckl7s4+hP4p6P+P9a8f8S/8fB/z3Nb3xS+K2jaFrk+kxwz3t1CcTGIgJG393J6nnnHT68VxK+ILLxHAbqxLrg4eNxhkPv/AI1vl9aDlyJ6k5pTkqfNbQ9a/ZfvvL8ReJtOJ+WeCC6QZ7qzox/Jk/Kvoivlr9nSYxfFd0Gds2lXCEZ7iWEg/oR+NfUteJmUeXEzX9bHqZbLmw0GFFFFcJ3BRRRQBwXi3xF4lbxivhrwbDpAvYtO/tK4n1TzCmxpGjRFVCDklGyxOAOxrGk8ZeNdWvb218O6boEFxpFjb3Oox31wziWaVC/lQuhChQqn942RyOOCa67xf4G0bxVcwXWofbYLyKJoBcWN1JbSNC33omZCNyH0NZerfCjwnqKW8f2S6s4IrVLF4bG7lt0uLdfuxShWG9Rk9eeetAHKaj8VtXX4jXPg61srG3vXvbSCG7uUd4LdJLZZmEjBgJJGbeqKpXOPbn2cZxz1rkr/AOHvh+9ttZgltnSPVJLeWXyn2GJ4ERImiI+4VCLjFdWilUVSxYgY3N1PuaAHVyfiE/avH3hGzHP2cXepEemyIQA/+TR/yK6yuT0n/T/iRr931j060t9OT2kbdPL+avb/AJUAdZRRRQAUUUUAFFFFABRRRQAVyvxRH/FCaqeyiNj7ASKSfoAM11Vc38S7d7r4eeJoYRmZtNuDH/viNiv6gUAc78VtNm1nwlrWm2rhJ7q1lhjLdNxUgZ9q/P8AvNMvrLUGsLu0nivVbaYWQh8/TvX6JaxcpeWMVzCcxzRrIv0IyP515R4q/jr0qOFWISV7HJWr+xu7XPD9BsZtO0C3trobZgCzL/dyxOP1r3T9l0geFfEynq2qFwP9ny1XP5q35V5Lqf35PrXsf7PVt/Z+j3ELAA31lDqIP97fdXan8lSL8x716OaRVOlTprp+iPJymTqVqlR9f1Z43+1F4d1FPF6a4sLy6bLAkRkUZETrnhvQHIIPua848BabdS6tHfeW62sKtmQjAYkEYB79c19l+J+jf59K8d8Vf6z/AD7VjgsFGdVVW9tTpx+KcKMoJbqxU+G0iR/FPwqXYKDeMoz3JhkAFes/tFaFe+IfAWoWmmKZLpHSdYh1kCtkqPfGSB3IFeK+FPNT4geHLmL7lnfwzy8ZxGZUhY/h52fwr6h8T9H/AB/rU49KeKcfJDyz3cKn5n55Qafdz3n2SK2ma5B2mLYdwPuO3416ukDWumW9u53NFEsZI7kLivVvFv3Zfx/rXl2rv5VvPJ/dUt+QNd+XYSOHjKd73PPzTEOtOELbH0Z8EyD8E/DRHQwy/wDo6Svirxl4b1Lwx4gutO1SGUSpIwSUg4mXPDqe+f8A6x5r7W+D1mdK+GdvozjEmmTzwMCckbnMo/SUfhis7xX0f6/414VGh7dJXse/Vqey1sfNHgfTLrT9Jle8jeJp3DLG4wQoHXHbNej/AANdV+Le1iAW0mcD3PmRnH5A1na//wAfTVq/Bu28vxtHqpHyLPHp27GceZb3Uh+nMUQ/EV7WNpxoYJU15fnc8LBTdbHym/P8jP8A2jNOuL20hltlL/Z5S7oOu0qBkfTivn2GJ5ZAqg+/tX1P8U/+Wv8An0rwfVepry5YVTSnc9P624TdOxz1x9xvoa++vCTiX4Y+E5FQRq+kWjBF6KDAnAr4S0uzOo6vY2IGTdXEcGPXcwX+tfdPhAhfh/pVv/z5o9iR6GFzER7YKYx2rn/5eHVD4D4U8Y+HNS8N6/dWGpQyh1kOyVgSJlzw6nvn/wCsea6vwPptzYaXK93G8RnYMqOMEADrjtn+lfR3in+L/PpXkes/8fL17OXYKMKntbnj5rim6Xs7bnpX7MswaXxlDg5QWb5+onH/ALLXn/7V3h3UZtcsddt4pJrBLf7NLsGfKYOzBiOwO7Gf9n6V2H7NXmw+IPErMcQ3sSrGPU24Tcf/ACZUfnXo3inpJ+P9a8+rBVq9SPmz0aEnToQfkj4m8F6bdXWrwXMcbi2hbc8uPl4HTPqfSvRYmVPEWgs5CquqWhJJwAPOWux8W/eP1/xrjDZve6lbrErM9us18AvX/R4JJh+ZjA/HHevTWHjhsFNXvdM8idZ4jHQ0tax9EftEaFe+Ivh7qdlpgZ7sFJkiX/lrsYEr9cZx7gV8OxadezX32KO0nN3u2mHYQwPuO341+iviB1kiDoQyMNykdwcV5J4p6P8A59K8qjhFiLXdj262IdFNpXPHoLZ7PTLa2lbdJFEiMfcACvpj4ZIZPg74eQMyFrMgMvUfM3Ir5z1H7zV738Dr4X3wb0c/xQtcRMPTEzlf/HSp/GvSzWKiqaX9bHkZO3KVRv8Arc+LPE/h3UvDetT6Zqds8dxG5VTtO2UZ4ZT3BruPBWm3WnaK32yN4nmkMixuMEDAGSO2f8K+j/Ff8VeP65/x9NSy3BxhP2tys2xLlS9nY7X9mz/kdfEP/YNi/wDRpri/2sPDmot4otdfhhkm042y27uoz5LKzHn0BDdfXNdP+zv5kPxFv52OLa50+S1H/XVHikA/75Zj+FeueKuj/jXDiIKriJx8z0MLJ08NB+R8SeA9Lu7jV4b1InW1g3FpSPlJwRgHua9b8DyLF8RfC7t93+0Yl/E5UfqRW34u/i+v+NcfYX39m+KPD13gkQ6pau2P7olUt/46DXpwwyw+CnG97pv8Dyatd1sdB22svxPZv2oPD9/4h8C+XpUbTT2l0l00KAlpFCupAHc/PnHtXxxp+mXmoXotLW3kefOCu0jb7t6D61+h3ibo1eQeLOkleVQwaxDV3Y9mviHRTsjyudDFAsZO4qoXPrgV7v8As3uW+DkKlAuy8uRkDG7Lk5P5/livCtSYIkjHooJNfQnwXtG0rwZdaVLxLb/ZZSv/AF0sbd2IHYbzIPwzXoZw0nTj6/oeXkib9pL0/U+R/i94c1LQPHWsHUIZPJurqW4guMHbKrsWHPrzyKvfD/S7uztLq6uoniSfaI1cYLAZ5x6c19S+Kej/AI/1rx/xL/x8H/Pc1OXYOKqqrfY1zTEv2Lp23N/9nr/krcX/AGDrn/0KKvquvmT9mq2MvxJ1K5AO230p4z9ZJoyP/RR/WvpuvNzN3xUvl+SO3LFbCw+f5hRRRXAd4UUUUAFFFFABRRRQA2WRIonklYJGgLMzHAAHUmuV+GMbSeF11WZGSfWZ5dUYMMELK2YlI9Vi8tf+A1B8QXfV5bHwhaMwk1bL3zKcGKxQjzTnsXysQ/3yf4TXYxokUaxxqqIoCqqjAAHQAUAOooooAKKKKACiiigAooooAKZLGk0TxSqGjdSrKe4PWn0UAeUeFpG/4Qiws5iTPpofTJc9d1uxhJP12BvxFcX4q/jruNei/sHxxfWzDbY68v223bsLmNQk0f4osbj1xIexrh/FX8de3lzvY83G7M8k1yQxRXDopZlBKqOrHsPzr6Vj0g+ErzwHbHiP+y30SU5+9MsaSoc/9sZ/++q8b+HHh4+KPiTp1oybrOxkGoXZxwFjbMan/ekC8dwrV9IfEPSbnV/C9wumqG1S0dL2yBON00TB1QnsGwUPs5qc4rqVaMF9n9THJ6LhSlN/af5HDeJ+jf59K8d8Vf6z/PtXq1/qVvq+lQahZsTBcIHXIwR0yCOxByCOxBrybxhKkKvLKwWNAWZj2AFejl7VrnNmSvFo2PhF4an1+LxxNbAi4h0g2dq3X9/IfMH5GGI/jXsNzqUWs6FZanbf6m8t0uE+jruH86sfAvw1L4b8AW322IxajqTm/uUYYZC4ARD7qioCPUGufSM6LqWseG5vlW2la7sc8b7WViwA9djl4/YBPUV4rrKriZT7s9SjRdHDxg+iOG8W/dl/H+tedw6a2t6zp2kICTqF5FanH913Ac/QLuJ+leieLfuy/j/Wn/s/+Hm1fx5NrMqE2WioVRiODcyLgD6rGWJ/66LXtVqyo4ST76feeP7F1sXBdtfuPVOLDxx4osCoVLyO31SL0YmMwOB9PIQn/fHrXJ+K+j/X/Guy+KUJ019L8URjEenM9vfED/l0m2hmPsjrE59FV64zxVyrkdP/ANdeRl7u7Hs4vY8f1/8A4+mr0H4eaS9p8EtV8QlDvTV11RWA5MFtIiyD6bY5/wDvqvPtehubrUIrPT4/Nv7uRbe2j/vSMcL+HcnsATX1v4e8O2ej+ELHw8EWazt7RbRww/1o24Yn/e5J+prtzmsuWFJep5uU0X7SdV+h85fFIgrIQcg8gj8K8H1Xqa9j8ZQXGm211ot+Wa80p/srO4wZYxjypf8AgSbT9dw7V45qvU1nTd6N0VVVsTY6L4C6M2ufF/w1Bt3R29z9skOOFEQMgJ/4Eqj8a+stM/0PUfFOksAv2fUnuogO8dwqzbv+/jTD6qa8x/Y58IvFDq3i26jKicfYbMkY3IGBlYeo3BVz6o1eqfESNtH8S6XrwGLK8QaVfN/cJYtbufYO0ifWYV5XN+9uevFWgcR4p/i/z6V5HrP/AB8vXrnin+L/AD6V5Y+kXHiLxHZ6HYlhc6jMIAwH+rTGZJP+AoGP1AHevp8NUVKk5y2SPncdTdWcYR3bPUvhzpjaF4M8Aay6bTf3V1HO2Okd2C0R+hMNsPxFdL4p6Sfj/Wu18U+G01LwRcaHpuy2aOBBYt2hliKtC30V0Q/hXm8uqrreixXwiaCV1KzQMfmglUkPG3urAj8K8DCT5qjb3Z7taKjBJdDy/wAW/eP1/wAa1/gHoaa1491F7lC1paaZJHJjs052L/46stY/i9gu5mICjJJPbrXtX7O/h2TSPBB1O6jKXetS/a9rDlYcARL/AN8jf9XNetmVZQwqh1kePgaLnjHPpEZ4buZLjwPpaXJzd2sX2K47fvoD5UnHb5kPFcN4p6P/AJ9K7jVojoPjTU9PcbbPWM6lZsenmgKs8Y9+Ekx33v6Vw/ino/8An0rly53sehjtmeS60ZPKmFupedvljQdWc8KPxJAr6R8K6Ynhe91nwwmBFbwWd3B6FDAsDY/4HbMT/v8AuK8m+FPh5vEvxLsEZN1lpTLqN0ccAqf3K/UyAN9I2r3D4mwnS9Q0jxOmRBblrDUCB0t5Su1z7JKqc9ldzSzWupYhQX2f1MMoouFGU39p/gji/Ff8VeP65/x9NXsHiv8AiryLVrS71LVrfTdNTfqF9Kttbr/tt3Psoyx9Apr08JNU6bnLZI4swg6klCO7Z6P8MtN/sf4d+H/EzgKJfELSysR/ywlU2S5PZd3lv+vrXdeKuj/jXWT+EbF/h+fCcZMdkLAWKSAfMmE2q/8AvAgNn1rzmLU59U0JHv0EWpwFra+iH/LO4ThwPYnkHupB714OGqOdVye71PcqQUKSiumh5p4u/i+v+NUPh14YPi7xdPp4xiLS7yXcf4XeMwoc9jmUsP8Adz2q/wCLv4vr/jXqP7NXh5rTw7feIrmMrLq8ii33Dn7NHkIf+BMzt7gqa9fMKyp4Tl6yPGwlF1MZzdImtFqg1vwxpup4w13bRzMvdWKgsp9wcj8K828WdJK7h4f7B17WfD0mFheR9T0//ahlctIo/wByUvx2V0rh/FnSSufLnezO7H7M8xubGTVbq30yDPnX88dmmOoMjBM/huz+FfUd/Emk/EKe3jQR22p6RG0SjpvtnKt+OyeL8E+teRfAnw82t/EQalIhNjoiGUtjhrh1Kov4KXY+h2ete1fFS1mTRbXXbKJpLnRJ/tbIgy0luVKTqB3PlsWA7si1hmtdTxNltHQWU0XTw/M/tanFeKej/j/WvH/Ev/Hwf89zXrviGaK5txPbyLJDKodHU5DKRkEH0xXj/ipmWY+WjSysQkcajLO5OFUe5JAH1r1cDJRjzPY4cyi5LlW561+y5ppWy8S6uyY+0XMdnGx7rEpY49t0pH1X2r3OuZ+G3hv/AIRLwRpWjuVa4hj33Dr0aZyXkI9tzHHtiumr5ivU9rUlPuz36FP2VOMOyCiiisjUKKKKACiiigAqnrGp2mjaVdajqMwhs7WMyyueygdh3PYDueKuVwsf/FdeIll+/wCFtInzH/d1C8Q/e94oiOOzSDP8HIBoeBdNu9t54g1qEw6zq5V3hf71rAufKt/qoJZv9t37YrqqKKACiiigAooooAKKKKACiiigAooooAxfF3h218T6O1hdvJEyuJoLiI4kt5V+7Ip9Rz7EEg8E15LqngLxrczm1MOjzDOBfi5aNCv95otpYH/ZBI/2q90orWlXnRd4OxnUpRqK0kcn8OfBNn4J0d7eCQ3N/csJby8ZcGZ8YGB/Cg6Kvb3JJPWUUVm25O73LSUVZHl/i7wFqMWoXN/4SNs8N45mutOuZDGvmnlpYnAO0seWUjBPOVOc4vhX4T317rttqfjEWsdpayCWHToJDL5rjkGZiAMA4OwZBIGTjivaqK1jiKkYOmnoZyowlLma1CuX8deFE8S2lvLb3H2LV7Ms1pdhdwTdjcjrxujbAyMjoCCCAa6iisk2ndGr1PBr34deMtXuBbXMWk2EZOJbxLlplA7mOPYpY+zbR7nv6/4O8N2HhPw9a6Rpat5MIJaRzl5nPLSOe7Mck/kMAAVtUVrVr1KqSm9jOFGFNtxW4yeGO4gkguI0khkUo6OMqykYII7givHNb+HviHTAbTw/9m1TSBxbx3FwYp7Ze0ZYgiRR0DEhgMA7utezUVNOrKk+aLKnBTVpHl3wz+GTaFqx1/xFJb3GshSlvDBlorRTwxDEAs5HBbAwOAOST6jRRSqVJVJc03dhCEaa5YqyPOPi78NE8bW8d5p1wllrsEflJK4Jjnjzny5Mc4ByQw5Uk8HJB8G0D4F63qvjWTRfEd1aabBBAl3K1vKZZJomZl/dfKB1QgluV3KdpzX2BXIfEBH0w6f4qtkZ5NGZzdIgJMlk4AnAA6ldqSAdzFjvVRrTjHkT0IlQpynztanR6Nplnouk2mm6Xbpb2VrGsUMSdFUDj6/U8ml1fTbTWNLutO1KBbizuozFLE3RlIwfp9R0qxBLHPDHNA6yRSKHR1OQykZBB9KfWRqeJ614B8WWz/ZLA2esWYO2G5nuPImVewlG0hiB/GvJ67Qa6n4XfDpfCctxqmqTxXeu3SeWzxA+Vbx5z5ceeTkgEscFsDgAYr0OitpYipKHs29DJUYKXOlqFeb+NfAt9LqNzq3hWS2We7+a8sLlikU7gYEqOAdkmAAeCGwM4IyfSKKzjNwfNHc0lFSVmeG6L8JtS1rVobnxgtra6VE4kNjDL5slyQchZGwFVPUDJYcZHOfcQAoAAAA4AFLRV1a06z5pu5FOlGmrRRh+MPDdt4n0n7HcSSW88Tie2uoseZbyjo65+pBHQgkHrXk2peAfG15P9leDR25x9vW5dYyP7xi2lgf9nJH+13r3WiilXnR1g7BUpRqK0kcv8PPBlj4K0M2Vo7XF1M3m3d24w88mAM47KAMBRwB6nJPRXlrBe2k9rdwpPbTo0csUi5V1IwQR3BFTUVm25O7LSSVkeLa18PvEunD7Jov2bV9MX5bc3NwYriBOyOSCJAOgfIbHUE8nd+GHw0Ph3UH1zXpYLnXHQxxJDkxWiH7wQkAsxxy5A44AHOfTKK1eIqOHs29DNUYKXPbUK8/8c+CLq+1GTWfDUtvDqMyBLu2uCVhuwowrFgCUkA4DYORgEcAj0Cis4ycXdGjSkrM8IsfhPrXiDUkPilbbTtIVt0sFvOZZrgf3NwACKe5ySRwAvUe528EVtbxQW8aRQxKESNBhVUDAAHYAVJRV1a06zvN3Ip0oU1aKOb8b+FovE1hCEnNnqdoxls7xV3GJyMEEfxIw4Ze/HQgEeWX/AMPPGWqXP2WWHSLRCcPei5aRAv8AeWPYGJ/2SQP9qvd6KdLEVKPwOwVKUKnxIwPBHhaw8H+HodK0wOyKTJLNJy88p+9Ix9Tj8AABwBW+RkYPSiism23dlpW0R5B4h+Hmr6bJKnhNbW70iRi6WE8phe1JJJWNsEMmSSFONvQEjAEnw++F1xZa9Fr/AIqe2e7tyWtLK3YyRwsf+WjuQNzgEgAABeTycEet0Vt9Yqcns76GfsYOXO1qFFFFYGoUUUUAFFFFABRRXD3+r33i67m0rwpcva6ZE5jvtbjAOCDhobbP3pOxk5VOcZbgAC67fXPirVZ/DehzSQ6fAdur6lEcbPW1iYf8tWH3mH3FP94jHYWFnbadYwWdjBHb2tugjiijGFRQMAAelQ6NpdloumW+n6Zbpb2kC7UjX8ySTySTkknkkkmrtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhAYEEAg8EGlooA4fww//CJa2PCl0dumT7pdElPQIMl7Qn+9H1T1j4/gNdxWX4k0S08QaVJY3u9VLCSKaJtskEinKSI38LKeQf5gkVi+F/EN7HqH/CPeLFjh1tATb3CjbDqUQ/5aR+jgEb4+oPIypBoA66iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio7ieK2gknuZUihjUs8kjBVUDqST0FAElUNb1jT9D0977VruK1tUIBeQ9SeiqOrMewGSewrmj4wutdJh8DWA1FDwdVut0Vinurfem/wC2Y2+rirmieEIbbUU1bXLuXWtcUEJdXKhUtweogiHyxD3GWPdjQBmta6x44/5CUdzonhkn/jz3FLu+X/pqQf3MZ/uA7z/EV5U9pZ2tvZWkNrZwRW9tCoSOKJQqoo6AAcAVNRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmeIdDsPEGnNZanCXj3B43RikkLj7rxuOVYdiOa06KAOITVdc8I/ufEcc2saKnCavbRbp4l/6eIVGTj/AJ6Rgg9Sq9a6zSdTsdYsI73Sry3vLSQZSaCQOrfiKt1zOp+CtJu759QsxcaTqjnLXmmSmB3PrIo+ST/gatQB01FciLPxrpwItdU0jWox91b+BrSX/gUsW5T+EQp39veJoBi68HSzMOv2DUoJAfp5piP5gfhQB1lFfPUvxm8W6d8UtQ8OR+E77WbVXRxbIsX2y0DgHa7QvJEVGeMlTj7xzzXv1jPJc2cM01tLaSSIGaCYqXjJ/hJUlcj2JFAE9Feb3Pi7xZqGv6uvhXRdMvNI0a9SwuVuboxXNzJtRn8rjYoUSL94/Ng4o0jxd4s1vV3vNI0XTJvDEepyaaxe6KXbLHIY3nAICbQwPyZ3ECgD0iivIfhz8Vb7xt4mh0a2tLO3ktRcyajLIGAKpO0aJAucs23YzMeF3dMkCvXqACisXW/FWhaHdJbaxq1pZ3DoJFjmkCkqSQD9Mg/lWf8A8LE8If8AQxab/wB/hQB1VFcr/wALE8If9DFpv/f4Uf8ACxPCH/Qxab/3+FAHVUVyv/CxPCH/AEMWm/8Af4Uf8LE8If8AQxab/wB/hQB1VFcr/wALE8If9DFpv/f4Uf8ACxPCH/Qxab/3+FAHVUVyh+InhP8A5Z63azHqRDulI+oUHFH/AAnelyHFlZa/eN/0x0a6C/8AfbRhf1oA6uiuT/4SbWrn/kG+DtVwekl9cW9uh9OA7OPxSk2+OL7G6Tw9oqEchFlv3H0J8lQfwI+tAHW1h634s0LRZ1t9R1KBLxvuWkeZbh/92JAXb8AazR4Ka858Q+Idb1XPJhFwLSH6bIAhI9mLVt6HoGkaDA0Oi6ZZ2EbHLi3hVN59WIGSfc80AYX9t+JdZO3QNCGm25/5ftbOw49Vt0O9vo7R0sPge2vJ0ufFd9c+IblGDrHdALaxsDwUt1+TjsX3sP71dfRQAgAUAAAAcACloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIba0trUym1t4YTK5kk8tAu9z1Y46k+tTUUUAcPr3wx0DW9ZuNQum1GNLt45b6ygu3jtr10xtaWMcMRtXpjOBnND/DHQG8Rf2ru1FUN6NSOni7YWbXWc+cYum/PPpnnFdxRQBx9j8PdGsY9CFo13FNo13Pd206yDzD5zu0sbHGCjFyCMdhzkZrsKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A luminal cholecystokinin (CCK) releasing factor (LCRF) stimulates intestinal CCK secretion. LCRF is normally secreted in the intestinal lumen, where it is exposed to pancreatic enzymes, such as trypsin. Under basal conditions, LCRF is inactivated by even small amounts of pancreatic enzymes. However, following a meal, food competes for enzyme binding, allowing LCRF to interact with CCK cells to stimulate hormone secretion. CCK in the circulation stimulates pancreatic secretion that, upon digestion of food, restores LCRF and CCK secretion to basal levels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Liddle RA. Am J Physiol 1995; 269:G319.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7393=[""].join("\n");
var outline_f7_14_7393=null;
var title_f7_14_7394="Patient information: Thalassemia (The Basics)";
var content_f7_14_7394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16747\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36948\">",
"         Organs inside the abdomen",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Thalassemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/thalassemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15196136\">",
"      <span class=\"h1\">",
"       What is thalassemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Thalassemia is a condition that affects the red blood cells. The red blood cells are the part of the blood that carries oxygen. Normally, red blood cells carry oxygen to all of the organs in the body.",
"     </p>",
"     <p>",
"      In thalassemia, the body doesn&rsquo;t make enough red blood cells. When a person has too few red blood cells, it&rsquo;s called &ldquo;anemia.&rdquo;",
"     </p>",
"     <p>",
"      Thalassemia is a life-long condition that people are born with. It is caused by an abnormal gene. If people get this abnormal gene from both their mother and father, it&rsquo;s called &ldquo;thalassemia major.&rdquo; If people get this abnormal gene from only 1 parent, it&rsquo;s called &ldquo;thalassemia trait.&rdquo; Thalassemia trait doesn&rsquo;t usually cause any of the symptoms of thalassemia major.",
"     </p>",
"     <p>",
"      There are many different types of thalassemia. This article discusses a serious form called &ldquo;beta thalassemia major.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196151\">",
"      <span class=\"h1\">",
"       What are the symptoms of thalassemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms usually start after a baby is a few months old. Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pale skin",
"       </li>",
"       <li>",
"        Acting cranky or upset",
"       </li>",
"       <li>",
"        Not growing as much as expected",
"       </li>",
"       <li>",
"        Swelling of the belly",
"       </li>",
"       <li>",
"        The skin or white part of the eyes turning yellow",
"       </li>",
"       <li>",
"        The bones of the face or skull being wider than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196166\">",
"      <span class=\"h1\">",
"       Is there a test for thalassemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A blood test can show if someone has thalassemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196181\">",
"      <span class=\"h1\">",
"       How is thalassemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with thalassemia and severe anemia are treated with blood transfusions. A blood transfusion is when a person gets blood that was given (donated) by another person.",
"     </p>",
"     <p>",
"      Although blood transfusions help treat thalassemia, they can also cause problems. That&rsquo;s because the donated blood has iron in it. When people get a lot of blood transfusions, their body gets too much iron. Too much iron can damage the heart and liver.",
"     </p>",
"     <p>",
"      People getting blood transfusions for their thalassemia need treatment to get rid of the extra iron that builds up in their bodies. Treatment to get rid of this extra iron is called &ldquo;iron chelation.&rdquo; Doctors can use different medicines for iron chelation.",
"     </p>",
"     <p>",
"      Thalassemia can sometimes be cured with a procedure called a &ldquo;bone marrow transplant.&rdquo; This procedure involves replacing the cells in the bone marrow (the inside part of bones) with healthy cells. These healthy cells come from another person (the donor). But not everyone with thalassemia can have this procedure. That&rsquo;s because it can be done only if a person and his or her donor meet certain conditions.",
"     </p>",
"     <p>",
"      Some people with thalassemia will need surgery to remove an organ called the spleen (",
"      <a class=\"graphic graphic_figure graphicRef61816 \" href=\"UTD.htm?36/5/36948\">",
"       figure 1",
"      </a>",
"      ). That&rsquo;s because the spleen removes red blood cells from the blood, which can make anemia worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196196\">",
"      <span class=\"h1\">",
"       What can people with thalassemia do to stay healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with thalassemia should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        See their doctor for regular follow-ups, and follow his or her instructions about tests and treatment.",
"       </li>",
"       <li>",
"        Avoid taking vitamins with iron in them.",
"       </li>",
"       <li>",
"        Take a vitamin called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        (folate), if the doctor or nurse recommends it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196211\">",
"      <span class=\"h1\">",
"       What if I have a child with thalassemia and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a child with thalassemia, it&rsquo;s possible that your future children will have thalassemia, too. Talk with your doctor to find out how likely it is that your future children will have the disease.",
"     </p>",
"     <p>",
"      If you do get pregnant, you can choose to test your unborn baby for thalassemia. This can be done in different ways.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15196226\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/14/7394?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16747 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7394=[""].join("\n");
var outline_f7_14_7394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196136\">",
"      What is thalassemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196151\">",
"      What are the symptoms of thalassemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196166\">",
"      Is there a test for thalassemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196181\">",
"      How is thalassemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196196\">",
"      What can people with thalassemia do to stay healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196211\">",
"      What if I have a child with thalassemia and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15196226\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36948\">",
"      Organs inside the abdomen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7395="Chronic diarrhea in adults";
var content_f7_14_7395=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic diarrhea in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/14/7395/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7395/contributors\" id=\"au6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/14/7395/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7395/contributors\" id=\"se4632\">",
"       Lawrence S Friedman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/14/7395/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7395/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/14/7395?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Chronic diarrhea is defined as loose stools that last for at least four weeks. This usually means three or more loose stools per day. There are many possible causes of chronic diarrhea. Treatment is aimed at correcting the cause of diarrhea (whenever possible), firming up loose stools, and dealing with any complications of diarrhea.",
"    </p>",
"    <p>",
"     Chronic diarrhea can have a substantial impact on your quality of life and overall health. At its mildest, diarrhea is an inconvenience; at its worst, it may be disabling and even life threatening. Fortunately, effective treatments are available.",
"    </p>",
"    <p>",
"     This article will focus on causes of chronic diarrhea in developed countries, such as the United States. More detailed information about chronic diarrhea in developed countries is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"      \"Approach to the adult with chronic diarrhea in developed countries\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHRONIC DIARRHEA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     A wide range of problems can cause chronic diarrhea; some of the most common causes include irritable bowel syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), malabsorption syndromes, and chronic infections. There are also many other less common causes of chronic diarrhea.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Irritable bowel syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;Irritable bowel syndrome (IBS) is one of the most common causes of chronic diarrhea. IBS can cause crampy abdominal pain and changes in bowel habits (diarrhea, constipation, or both). IBS can develop after having an infection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Inflammatory bowel disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several types of inflammatory bowel disease, two of the most common of which are Crohn's disease and ulcerative colitis. These conditions may develop when the body's immune system attacks parts of the digestive tract. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Intestinal infections are a cause of chronic diarrhea. Infections that cause chronic diarrhea can be seen in people who travel or live in tropical or developing countries. Intestinal infections can also develop after eating contaminated food or drinking contaminated water or unpasteurized (\"raw\") milk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"      \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Endocrine disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;An overactive thyroid (hyperthyroidism) can cause chronic diarrhea and weight loss. Diabetes can cause chronic diarrhea if the nerves that supply the digestive tract are injured.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Food allergy or sensitivity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Food allergies and hypersensitivity can cause chronic diarrhea. People with celiac disease are sensitive to gluten, a major component of wheat flour which can cause diarrhea and weight loss. Patients with lactose intolerance develop diarrhea and gas when they ingest milk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medicines (prescription and nonprescription), herbs, and dietary supplements can cause diarrhea as a side effect. To determine if a medicine could be the cause of your diarrhea, review your list of medicines with your doctor, nurse, or pharmacist. This information may also be available on the medicine bottle or paperwork that comes with most prescriptions.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CHRONIC DIARRHEA EVALUATION",
"     </span>",
"    </p>",
"    <p>",
"     You should seek medical attention if you have loose or watery stools that last more than three weeks. You may need to be seen sooner than this if you have complications of diarrhea (eg, bloody diarrhea, fever, dehydration, or weight loss).",
"    </p>",
"    <p>",
"     During your visit, it is important to mention when your diarrhea began, any recent changes in medicines or medical problems, and if you have had accidents (leaking or smearing of stool in the underwear).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood, stool, and urine tests can help to find the underlying cause of diarrhea. Special breath tests are used to test for lactose intolerance, or bacterial overgrowth of the small bowel. If these tests do not find the cause, other approaches may be needed, including x-rays or procedures, such as colonoscopy or sigmoidoscopy. Your primary care provider can order these tests or refer you to a specialist (a gastroenterologist). In many patients with chronic diarrhea, a specific, curable cause cannot be identified. These patients may have irritable bowel syndrome. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In some cases, your doctor or nurse will recommend a trial of treatment before more invasive tests (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Treatment trial'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      CHRONIC DIARRHEA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of chronic diarrhea aims to eliminate the underlying cause (if the cause is known), firm up the bowel movements, and treat any diarrhea-related complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treating the cause",
"     </span>",
"     &nbsp;&mdash;&nbsp;The underlying cause of chronic diarrhea should be found and treated whenever possible. For example, infections may be treated with antibiotics. In people with Crohn's disease or ulcerative colitis, long-term treatment and follow-up is needed.",
"    </p>",
"    <p>",
"     In some cases, treatment may be as simple as eliminating a food or medicine.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       For people with lactose intolerance, this may include foods or drinks that contain lactose (",
"       <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Other ingredients that are known to cause diarrhea include sugar-free products made with sorbitol and foods made with fat replacements (eg, Olestra&reg;).",
"      </li>",
"      <li>",
"       Certain medicines can also cause diarrhea (such as laxatives and antacids).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treating diarrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, the goal is simply to have less diarrhea. This approach is often used before testing, when the results of tests are normal or not helpful, or if diarrhea is caused by a chronic medical problem.",
"    </p>",
"    <p>",
"     Diarrhea treatments include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bismuth (sold as Kaopectate&reg;, Pepto-Bismol&reg;)",
"      </li>",
"      <li>",
"       Treatments that bulk the stools, such as a high-fiber diet or fiber supplement (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"        \"Patient information: High-fiber diet (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Antidiarrhea medicines, such as loperamide (sold as Imodium&reg;, available without a prescription) or prescription medicines, such as diphenoxylate (Lomotil&reg;)",
"      </li>",
"      <li>",
"       Octreotide, a prescription medicine that might be given to people with severe diarrhea",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Treatment trial",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your doctor or nurse might recommend trying a treatment before further testing. This approach can help to narrow down the list of possible causes of your diarrhea.",
"    </p>",
"    <p>",
"     Treatments that might be offered include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A trial of antibiotics, for an infection",
"      </li>",
"      <li>",
"       Stopping a medicine",
"      </li>",
"      <li>",
"       Changing your diet, for a possible food allergy or problem absorbing nutrients (such as lactose intolerance)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Treating complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic or severe diarrhea can lead to potentially serious complications, including dehydration and malnutrition. While you are being evaluated, you should be sure to drink plenty of fluids. You are drinking enough fluids if your urine is a light yellow color.",
"    </p>",
"    <p>",
"     If you are not able to drink enough fluids and you become dehydrated, you may be given fluids into a vein (IV) to replace the fluids and electrolytes (salts) lost in diarrhea. This will not cure your diarrhea, but it can prevent more serious complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498522430\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5511446\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/36/25154?source=see_link\">",
"      Patient information: Microscopic colitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5511496\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=see_link\">",
"      Cyclospora infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=see_link\">",
"      Etiology and pathogenesis of small intestinal bacterial overgrowth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"      Lactose intolerance",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=see_link\">",
"      Lymphocytic and collagenous colitis (microscopic colitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6424?source=see_link\">",
"      Treatment and prevention of giardiasis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/diarrhea.html\">",
"      www.nlm.nih.gov/medlineplus/diarrhea.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/diarrhea/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/diarrhea/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/14/7395/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/14/7395?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7395/abstract/1\">",
"      Juckett G, Trivedi R. Evaluation of chronic diarrhea. Am Fam Physician 2011; 84:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7395/abstract/2\">",
"      Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7395/abstract/3\">",
"      Habba SF. Chronic diarrhea: identifying a new syndrome. Am J Gastroenterol 2000; 95:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7395/abstract/4\">",
"      Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_14_7395=[""].join("\n");
var outline_f7_14_7395=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHRONIC DIARRHEA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CHRONIC DIARRHEA EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           CHRONIC DIARRHEA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?32/38/33388\" title=\"table 1\">",
"           Lactose content of different foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7396="Retropalatal anatomy MRI";
var content_f7_14_7396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Normal retropalatal anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial spin echo MRI in a normal subject in the retropalatal region. The tongue, soft palate, parapharyngeal fat pads, lateral parapharyngeal walls, parotid gland, subcutaneous fat, teeth, and mandibular rami are all highlighted on this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schwab, RJ, Gupta, KB, Gefter, WB, et al. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing. Significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 1995; 152:1673. Official journal of the American Thoracic Society. Copyright &copy;1995 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7396=[""].join("\n");
var outline_f7_14_7396=null;
var title_f7_14_7397="Disseminated intravascular coagulation acral purpura";
var content_f7_14_7397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acral purpura in disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple purpuric lesions are present on the hand of this patient with disseminated intravascular coagulation. Several lesions exhibit a retiform shape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7397=[""].join("\n");
var outline_f7_14_7397=null;
var title_f7_14_7398="Diagnosis of schistosomiasis";
var content_f7_14_7398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of schistosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7398/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/14/7398/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis is caused by infection with Schistosoma haematobium, S. mansoni, S. japonicum, S. mekongi, or S. intercalatum. The various species are associated with different clinical complications. The clinical features also differ in acute and chronic infections.",
"   </p>",
"   <p>",
"    The diagnosis of schistosomiasis will be reviewed here. The epidemiology, pathogenesis, clinical features, treatment, and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many people who are infected with schistosomiasis are asymptomatic and only investigated because infection is suspected on the basis of epidemiologic history (eg, travelers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine blood or urine tests may show nonspecific abnormalities. The diagnosis of schistosomiasis can be confirmed by microscopy with egg identification, by serology, or by consistent radiologic findings in the appropriate clinical scenario. A diagnosis of schistosomiasis should prompt initiation of treatment, even if the patient is asymptomatic, since adult worms can live for years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonspecific laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A routine full blood count may show eosinophilia in infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/2\">",
"     2",
"    </a>",
"    ]. The degree of eosinophilia relates to the stage, intensity, and duration of infection, as well as to genetic determinants of the host [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/3\">",
"     3",
"    </a>",
"    ]. Most studies suggest between one- and two-thirds of infected patients have a peripheral eosinophilia, which is frequently most marked early in the course of infection. Eosinophilia is also a frequent finding in patients with Katayama fever, a hypersensitivity reaction seen with acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\", section on 'Acute infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A full blood count may also reveal anemia from chronic blood loss in patients with intestinal or urinary tract schistosomiasis.",
"   </p>",
"   <p>",
"    Patients with hepatosplenic schistosomiasis may have thrombocytopenia secondary to splenic sequestration. Liver function tests including transaminases are usually normal since fibrosis occurs mainly within blood vessels and not within the liver parenchyma itself. However, a mild increase in alkaline phosphatase and gamma-glutamyl transferase may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. haematobium infections are often associated with hematuria as detected on dipstick. Patients can be questioned about macroscopic hematuria or a dipstick examination of the urine can be performed. Studies have shown that almost 100 percent of children under 12 years of age from endemic areas who have hematuria are infected with S. haematobium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. One study also found that 78 percent of British expatriates with eggs in the urine had hematuria on dipstick [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/11\">",
"     11",
"    </a>",
"    ]. This screening method is a technically simple and inexpensive way to alert the clinician to the possibility of schistosomiasis; however, the diagnosis should be confirmed by microscopy or serology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\", section on 'Chronic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demonstration of parasite eggs in stool or urine is often used for making the diagnosis of schistosomiasis and is required for species identification; however, the sensitivity of microscopy may be low, especially in light infections.",
"   </p>",
"   <p>",
"    S. haematobium eggs are usually found in urine, but may also be present in feces. The sensitivity of microscopic examination of the urine is maximized by collecting samples during the time of day when maximal egg excretion occurs (ie, between 10 am and 2 pm) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/12\">",
"     12",
"    </a>",
"    ]. The diagnostic yield can also be improved with sedimentation or filtration of urine. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Assessing intensity of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Eggs of S. mansoni, S. japonicum, S. haematobium, S. mekongi, and S. intercalatum are found in stool specimens. Concentration techniques improve the sensitivity of egg detection, but it has been estimated that 3000 to 6000 eggs per day must be excreted to be readily visualized using these tools [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Assessing intensity of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the intensity of infection is an important tool in endemic areas as many of the complications of schistosomiasis are related to the parasite burden. This is performed by quantitative sampling of defined amounts of stool (Kato-Katz technique) or urine (syringe filtration) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current infection can be determined by the presence of viable eggs, while treated infection will be associated with identification of only nonviable eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Morphology of different species",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different species of schistosomes are distinguished by morphologic differences in the eggs. The eggs have characteristic spines which can be seen on microscopy and which usually allow easy species differentiation (",
"    <a class=\"graphic graphic_picture graphicRef50678 \" href=\"UTD.htm?2/24/2432\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S. mansoni eggs measure 115 to 175 micrometers by 45 to 70 micrometers and have a prominent lateral spine.",
"     </li>",
"     <li>",
"      S. haematobium eggs measure 110 to 170 micrometers by 40 to 70 micrometers and have a prominent terminal spine.",
"     </li>",
"     <li>",
"      S. japonicum measures 70 to 100 micrometers by 55 to 65 micrometers and has only a small inconspicuous spine.",
"     </li>",
"     <li>",
"      S. mekongi eggs resemble those of S. japonicum but are smaller, measuring 50 to 80 micrometers by 40 to 60 micrometers.",
"     </li>",
"     <li>",
"      S. intercalatum also has a terminal spine but is larger than S. haematobium, measuring up to 240 micrometers in length.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also morphologic differences in adult worms of the varying species; however, since adult worms are rarely recovered, these differences do not provide any practical information. Epidemiologic clues may also aid species identification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other sites of egg detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis may also be diagnosed by finding eggs in tissue biopsy specimens of rectal, intestinal, liver, or bladder biopsies (",
"    <a class=\"graphic graphic_picture graphicRef63466 \" href=\"UTD.htm?10/13/10449\">",
"     picture 2",
"    </a>",
"    ). Rectal snips may reveal eggs even when multiple stool specimens are negative. In one study of 135 British expatriates with S. mansoni infection, 61 percent had eggs detected on rectal biopsy, whereas only 39 percent had ova detected in stool [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/11\">",
"     11",
"    </a>",
"    ]. Cystoscopy with bladder biopsy is unnecessary in most cases of S. haematobium infection, but can be performed if the diagnosis is suspected and eggs are not found in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eggs may also be detected in other ectopic sites, such as in bronchoscopic washings or transbronchial biopsies in individuals with pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, eosinophils may be present in the cerebrospinal fluid (CSF) of individuals with neurologic involvement. One review showed that 41 percent of individuals with spinal cord involvement had eosinophils present in their CSF; 85 percent of these also had antischistosomal antibodies detected in spinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are available that can detect antischistosomal antibodies in serum samples. Tests have been developed which use extracts of adult worms, cercarial antigens, or egg extracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lack of standardization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various techniques, including enzyme linked immunosorbent assay (ELISA), radioimmunoassay, indirect hemagglutination, Western blot, and complement fixation, are used in different assays. However, many tests have not been well-standardized; sensitivities and specificities can vary based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The particular assay",
"     </li>",
"     <li>",
"      Which gold standard is used for comparison",
"     </li>",
"     <li>",
"      The intensity of infection",
"     </li>",
"     <li>",
"      The specific schistosomal species being evaluated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, it is difficult to quote a single figure for the evaluation of the various tests used in different trials. The sensitivity and specificity of ELISA tests currently in use are generally reported to be &gt;90 and &gt;95 percent, respectively. Western blot techniques using species-specific antigens are often employed to confirm ELISA results and for species determination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Utility of the antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the serologic tests for schistosomal antibodies can distinguish between a past infection and current, active disease, which makes them unreliable for post treatment follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/19\">",
"     19",
"    </a>",
"    ]. This is a problem especially in endemic areas. However, a negative antibody test can rule out infection in endemic populations.",
"   </p>",
"   <p>",
"    Serology is a more specific diagnostic tool in travelers, who would not otherwise be expected to have schistosomal antibodies. These patients often have light egg excretion since the burden of infection is low. Antibody tests are generally negative during the acute presentation of Katayama fever, although serology often becomes positive before eggs become detectable. Seroconversion generally occurs within four to eight weeks after infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limitations of antibody tests, techniques to detect parasite antigens have been developed, but they are not yet commercially available. Two gut associated parasite proteins, circulating anodic antigen (CAA) and circulating cathodic antigen (CCA), are present in the blood during active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/4\">",
"     4",
"    </a>",
"    ]. Studies suggest this may be a useful way to identify a current infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/20\">",
"     20",
"    </a>",
"    ]. In most assays, these antigens are measured via a sandwich ELISA using monoclonal antibodies, which allows quantitation of infection intensity, in addition to a qualitative result. Assays that measure parasite antigens in stool",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine have also been developed.",
"   </p>",
"   <p>",
"    Antigen detection techniques have at least equal sensitivity to stool or urine concentration methods; combining these techniques improves sensitivity further in low-intensity infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/21\">",
"     21",
"    </a>",
"    ]. Antigen titers also correlate well with the determination of infection intensity by egg counts and with clinical severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. They can also be used to assess treatment efficacy post-therapy, since loss of circulating antigens indicates cure. Studies have shown that after successful therapy, antigen tests become negative as soon as 5 to 10 days post treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction assays are being developed for the diagnosis of schistosomiasis. One study, using patient urine samples, found that PCR-based techniques were 94.4 percent sensitive and 99.9 percent specific for the diagnosis of schistosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic techniques give an indication of disease severity by detecting complications of schistosomiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Liver involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound can be used to image the liver and may show periportal fibrosis around portal vein tributaries with late S. japonicum and S. mansoni infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/29\">",
"     29",
"    </a>",
"    ]. Splenomegaly, portal vein dimensions, and the presence of collateral vessels can also be detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=see_link\">",
"     \"Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT scans can show characteristic patterns in livers with established hepatic schistosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. MRI scans demonstrate heterogeneity of hepatic parenchyma, periportal fibrosis, and the presence of venous collateral pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/32\">",
"     32",
"    </a>",
"    ]; however, neither modality is consistently available in endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Urinary tract involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the kidneys and bladder by ultrasound in patients with S. haematobium infections may show irregularities in the bladder wall due to granulomas. Hydronephrosis, bladder polyps and tumors can also be detected. Calcification of the bladder wall may be demonstrated on plain x-ray; the characteristic appearance is often referred to as \"fetal head\" calcification. Ureteric strictures may also be detected by intravenous pyelogram (IVP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neurologic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT or MRI imaging may be utilized in patients with suspected central nervous system or spinal cord involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized systems for grading the severity of liver pathology have been developed by the World Health Organization (WHO) to correlate with clinical parameters, such as number of episodes of hematemesis from variceal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7398/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schistosomiasis is caused by infection with three main species, including Schistosoma haematobium, S. mansoni, and S. japonicum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonspecific laboratory tests may demonstrate eosinophilia or anemia. Patients with portal hypertension may also have thrombocytopenia; those with urinary tract involvement may have hematuria. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonspecific laboratory abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Demonstration of parasite eggs in stool or urine is often used for making the diagnosis of schistosomiasis and is required and for species identification; however, the sensitivity of microscopy may be low, especially in light infections. These microscopic tests are usually unrevealing in the initial six weeks following infection (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Microscopy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Quantification of parasite burden is important, since the intensity of infection is associated with increased risk of disease complications (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Assessing intensity of infection'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      None of the serologic tests for schistosomal antibodies can distinguish between a past infection and active disease. A negative antibody test is useful to rule out infection in endemic areas. A positive serology is clinically useful in a returning traveler, although serology may not become positive for at least a month following exposure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/1\">",
"      Warren KS, Mahmoud AA, Cummings P, et al. Schistosomiasis mansoni in Yemeni in California: duration of infection, presence of disease, therapeutic management. Am J Trop Med Hyg 1974; 23:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/2\">",
"      Pardo J, Carranza C, Muro A, et al. Helminth-related Eosinophilia in African immigrants, Gran Canaria. Emerg Infect Dis 2006; 12:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/3\">",
"      Mahmoud AA. The ecology of eosinophils in schistosomiasis. J Infect Dis 1982; 145:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/4\">",
"      Gundersen SG, Ravn J, Haagensen I. Early detection of circulating anodic antigen (CAA) in a case of acute schistosomiasis mansoni with Katayama fever. Scand J Infect Dis 1992; 24:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/5\">",
"      Nduka FO, Ajaero CM, Nwoke BE. Urinary schistosomiasis among school children in an endemic community in south-eastern Nigeria. Appl Parasitol 1995; 36:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/6\">",
"      Amali O. Estimation of prevalences of urinary schistosomiasis using haematuria. Cent Afr J Med 1994; 40:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/7\">",
"      Nwaorgu OC, Anigbo EU. The diagnostic value of haematuria and proteinuria in Schistosoma haematobium infection in southern Nigeria. J Helminthol 1992; 66:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/8\">",
"      Taylor P, Chandiwana SK, Matanhire D. Evaluation of the reagent strip test for haematuria in the control of Schistosoma haematobium infection in schoolchildren. Acta Trop 1990; 47:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/9\">",
"      Sarda RK, Minjas JN, Mahikwano LF. Evaluation of indirect screening techniques for the detection of Schistosoma haematobium infection in an urban area, Dar es Salaam, Tanzania. Acta Trop 1985; 42:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/10\">",
"      Stephenson LS, Latham MC, Kinoti SN, Oduori ML. Sensitivity and specificity of reagent strips in screening of Kenyan children for Schistosoma haematobium infection. Am J Trop Med Hyg 1984; 33:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/11\">",
"      Harries AD, Fryatt R, Walker J, et al. Schistosomiasis in expatriates returning to Britain from the tropics: a controlled study. Lancet 1986; 1:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/12\">",
"      Peters, P, Kazura, JW. Update on diagnostic methods for schistomiasis. Baillere's Clinical Tropical Medicine and Communicable Diseases 1987; 2:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/13\">",
"      Elliott DE. Schistosomiasis. Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am 1996; 25:599.",
"     </a>",
"    </li>",
"    <li>",
"     King, C, Mahmouud, AA. Schistosomiasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, Vol 2, Guerrant, R, Walker, DH, Weller, PF, (Eds), Churchill Livingstone, Philadelphia 1999. p.1031.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/15\">",
"      Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993; 7:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/16\">",
"      Shimazu C, Pien FD, Parnell D. Bronchoscopic diagnosis of Schistosoma japonicum in a patient with hemoptysis. Respir Med 1991; 85:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/17\">",
"      Schaberg T, Rahn W, Racz P, Lode H. Pulmonary schistosomiasis resembling acute pulmonary tuberculosis. Eur Respir J 1991; 4:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/18\">",
"      Ferrari TC. Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Medicine (Baltimore) 1999; 78:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/19\">",
"      Rabello AL, Garcia MM, Pinto da Silva RA, et al. Humoral immune responses in patients with acute Schistosoma mansoni infection who were followed up for two years after treatment. Clin Infect Dis 1997; 24:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/20\">",
"      Deelder AM, Qian ZL, Kremsner PG, et al. Quantitative diagnosis of Schistosoma infections by measurement of circulating antigens in serum and urine. Trop Geogr Med 1994; 46:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/21\">",
"      Van Lieshout L, Panday UG, De Jonge N, et al. Immunodiagnosis of schistosomiasis mansoni in a low endemic area in Surinam by determination of the circulating antigens CAA and CCA. Acta Trop 1995; 59:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/22\">",
"      de Jonge N, Kremsner PG, Krijger FW, et al. Detection of the schistosome circulating cathodic antigen by enzyme immunoassay using biotinylated monoclonal antibodies. Trans R Soc Trop Med Hyg 1990; 84:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/23\">",
"      Van 't Wout AB, De Jonge N, Tiu WU, et al. Schistosome circulating anodic antigen in serum of individuals infected with Schistosoma japonicum from the Philippines before and after chemotherapy with praziquantel. Trans R Soc Trop Med Hyg 1992; 86:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/24\">",
"      Hassan MM, Medhat A, Makhlouf MM, et al. Detection of circulating antigens in patients with active Schistosoma haematobium infection. Am J Trop Med Hyg 1998; 59:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/25\">",
"      Salah F, El Bassiouny A, Rabia I, et al. Human schistosomiasis haematobium: effective diagnosis of active infection using a pair of monoclonal antibodies against soluble egg antigen. Parasitol Res 2006; 99:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/26\">",
"      de Jonge N, De Caluw&eacute; P, Hilberath GW, et al. Circulating anodic antigen levels in serum before and after chemotherapy with praziquantel in schistosomiasis mansoni. Trans R Soc Trop Med Hyg 1989; 83:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/27\">",
"      van Lieshout L, Polderman AM, Deelder AM. Immunodiagnosis of schistosomiasis by determination of the circulating antigens CAA and CCA, in particular in individuals with recent or light infections. Acta Trop 2000; 77:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/28\">",
"      Sandoval N, Siles-Lucas M, P&eacute;rez-Arellano JL, et al. A new PCR-based approach for the specific amplification of DNA from different Schistosoma species applicable to human urine samples. Parasitology 2006; 133:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/29\">",
"      Richter J, Hatz C, H&auml;ussinger D. Ultrasound in tropical and parasitic diseases. Lancet 2003; 362:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/30\">",
"      Abdel-Wahab MF, Esmat G, Farrag A, et al. Grading of hepatic schistosomiasis by the use of ultrasonography. Am J Trop Med Hyg 1992; 46:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/31\">",
"      Yazdanpanah Y, Thomas AK, Kardorff R, et al. Organometric investigations of the spleen and liver by ultrasound in Schistosoma mansoni endemic and nonendemic villages in Senegal. Am J Trop Med Hyg 1997; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7398/abstract/32\">",
"      Bezerra AS, D'Ippolito G, Caldana RP, et al. Chronic hepatosplenic schistosomiasis mansoni: magnetic resonance imaging and magnetic resonance angiography findings. Acta Radiol 2007; 48:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5682 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7398=[""].join("\n");
var outline_f7_14_7398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonspecific laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Assessing intensity of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Morphology of different species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other sites of egg detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lack of standardization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Utility of the antibody tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Polymerase chain reaction assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Liver involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Urinary tract involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neurologic involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5682|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/24/2432\" title=\"picture 1\">",
"      Schistosome eggs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/13/10449\" title=\"picture 2\">",
"      Schistosomiasis on colonoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14985?source=related_link\">",
"      Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=related_link\">",
"      Treatment and prevention of schistosomiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7399="Reticular opacities PA I";
var content_f7_14_7399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reticular opacities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard International Labor Office film for small irregular t opacities, 1.5-3 mm in diameter (reticular opacities).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7399=[""].join("\n");
var outline_f7_14_7399=null;
var title_f7_14_7400="Diffusing capacity for carbon monoxide";
var content_f7_14_7400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diffusing capacity for carbon monoxide",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7400/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7400/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7400/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/14/7400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A test of the diffusing capacity of the lungs for carbon monoxide (DLCO) is one of the most clinically valuable tests of lung function. DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries. The test is rarely available in the outpatient office setting because the instrument costs more than $20,000 and requires much more skill and experience for its use and maintenance than does a spirometer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the DLCO test is convenient and easy for the patient to perform. The ten seconds of breathholding required for the DLCO maneuver is easier for most patients to perform than is the forced exhalation required for spirometry. Completion of two or three DLCO maneuvers also usually takes less time than pre- and post-bronchodilator spirometric tests.",
"   </p>",
"   <p>",
"    Standards for DLCO instruments, performance of the test, and calculation of the results were initially published by the American Thoracic Society in 1987, and updated in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The indications for DLCO measurement and the interpretation of the results will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DLCO is designed to reflect properties of the alveolar-capillary membrane, specifically the ease with which oxygen moves from inhaled air to the red blood cells in the pulmonary capillaries. The uptake of most soluble gases (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    or acetylene) is limited by (and varies with) pulmonary blood flow. In contrast, the strong affinity of hemoglobin for carbon monoxide (CO), combined with the enormous capacity of the red cell mass to absorb CO, make the uptake of CO less dependent on cardiac output. Thus, diseases in which the uptake of oxygen is reduced cause parallel decreases in the uptake of CO, as measured by the DLCO.",
"   </p>",
"   <p>",
"    Older textbooks suggest that thickening of the alveolar-capillary membrane (in interstitial lung disease) and loss of alveolar membrane surface area (in emphysema) are the primary causes of a low DLCO. However, subsequent experimental data suggest these and most other diseases that influence the DLCO do so by reducing the volume of red blood cells in the pulmonary capillaries. The total volume of blood in the lungs in healthy adults at rest is less than 150 mL; the volume of blood in the pulmonary capillaries and the DLCO are",
"    <strong>",
"     increased",
"    </strong>",
"    in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When pulmonary capillaries are recruited, as occurs during exercise",
"     </li>",
"     <li>",
"      When the patient is in the supine position",
"     </li>",
"     <li>",
"      During a Mueller (reverse Valsalva) maneuver",
"     </li>",
"     <li>",
"      When a left-to-right cardiac shunt is present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple clinical indications for measurement of DLCO, and there are no contraindications or adverse effects (",
"    <a class=\"graphic graphic_table graphicRef60997 \" href=\"UTD.htm?4/8/4235\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/3\">",
"     3",
"    </a>",
"    ]. However, most instruments are unable to measure the DLCO when the patient's vital capacity is less than approximately 1.5 liters. In addition, supplemental oxygen should be discontinued for about 15 minutes prior to (and during) the test, which may be difficult for patients who require continuous supplemental oxygen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Obstructive disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DLCO is an excellent index of the degree of anatomic emphysema in smokers with airways obstruction. A low DLCO correlates highly with a low mean density of lung tissue on lung CT scan and with the degree of anatomic emphysema [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smokers with airways obstruction but normal DLCO values usually have chronic \"obstructive\" bronchitis but not emphysema.",
"     </li>",
"     <li>",
"      Patients with airway obstruction from asthma have normal or high DLCO values [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with cystic fibrosis have a normal DLCO until their disease becomes very severe [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), the DLCO does not correlate well with the degree of dyspnea in chronic obstructive pulmonary disease (COPD), and following such patients with serial DLCO tests does not have well established clinical value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Restrictive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DLCO helps in the differential diagnosis of restrictive lung disease, which is identified by reduced total lung capacity (TLC) and vital capacity (VC). A low DLCO combined with reduced lung volumes suggests interstitial lung disease (ILD) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A normal DLCO associated with low volumes is consistent with an extrapulmonary cause of the restriction, such as obesity, pleural effusion or thickening, neuromuscular weakness, or kyphoscoliosis.",
"   </p>",
"   <p>",
"    Another common application of the DLCO is for detection of mild (early or preclinical) interstitial lung disease in high-risk patients, including those with [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/9,11-18\">",
"     9,11-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I sarcoidosis",
"     </li>",
"     <li>",
"      Extrinsic allergic alveolitis",
"     </li>",
"     <li>",
"      Chest radiation and cancer chemotherapy",
"     </li>",
"     <li>",
"      Use of drugs known to have pulmonary toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"       nitrofurantoin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lung, bone marrow, or renal transplants",
"     </li>",
"     <li>",
"      HIV-infection and high risk for Pneumocystis pneumonia",
"     </li>",
"     <li>",
"      Severe gastroesophageal reflux disease (GERD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The normal range for DLCO is wide; as a result, it is much more sensitive to obtain a baseline DLCO test prior to therapy and subsequently perform a follow-up examination. Changes in follow-up values of DLCO in patients being treated for interstitial lung disease are often more sensitive to improvement or worsening than are changes in TLC or VC [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal DLCO may be due to pulmonary vascular disease in those patients with chronic dyspnea but normal spirometry and lung volumes. Reduction in the DLCO is a sensitive indicator of [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic recurrent pulmonary emboli",
"     </li>",
"     <li>",
"      Idiopathic pulmonary arterial hypertension",
"     </li>",
"     <li>",
"      Pulmonary vascular involvement from connective tissue diseases and vasculitides such as systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prior to lung resection surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A very low DLCO increases the risk of postoperative morbidity and mortality in patients with lung cancer, although there is no consensus regarding the threshold below which surgery is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. A low DLCO has been identified as a major factor in the long-term outcome of lung volume reduction surgery (LVRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Disability evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the DLCO is also used for disability evaluation in patients with severe COPD or interstitial lung disease. A DLCO below 30 percent predicted (or less than 9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg) may qualify a patient for total disability according to Social Security standards, whereas American Medical Association and American Thoracic Society guidelines use a threshold value of 40 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=see_link\">",
"     \"Evaluation of pulmonary disability\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Need for oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low DLCO is the major predictor of oxygen desaturation during exercise, so a DLCO test may be worthwhile in patients presenting with dyspnea on exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. However, demonstration of arterial oxygen desaturation, using either pulse oximetry or arterial blood gas analysis, is generally required prior to initiating long-term oxygen therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     METHODOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all pulmonary function laboratories use a single-breath method, in which the patient quickly inhales a deep breath of 0.3 percent CO and 10 percent helium, holds their breath for 10 seconds, and then exhales quickly (",
"    <a class=\"graphic graphic_figure graphicRef60988 \" href=\"UTD.htm?9/35/9790\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/35\">",
"     35",
"    </a>",
"    ]. An alveolar sample of the exhaled gas is then analyzed for calculation of the dilution of helium and the uptake of CO.",
"   </p>",
"   <p>",
"    Inspiratory volume should be greater than 85 percent of the largest VC and the inspiratory time should be less than 4 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/2\">",
"     2",
"    </a>",
"    ]. There should be no evidence of a Mueller or Valsalva maneuver. The expiratory time should also be less than four seconds and the sample collection time less than three seconds. The first 0.75 to 1.0 L is discarded as dead space gas and then a sample gas volume of 0.5 to 1 L is collected for analysis. After a minimum of four minutes, the test is repeated; a longer interval may be needed if the patient has obstructive airways disease.",
"   </p>",
"   <p>",
"    If the results from two acceptable tests are within 2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg, the mean value is reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without a previous DLCO test, the patient's result is interpreted by comparing it with the predicted value. Based on criteria established by the American Medical Association and the American Thoracic Society, severe respiratory impairment is defined as a DLCO below 40 percent of the predicted value [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/2\">",
"     2",
"    </a>",
"    ]. Threshold values for mild and moderate reduction of the DLCO have NOT been standardized, but are suggested in the table (",
"    <a class=\"graphic graphic_table graphicRef60743 \" href=\"UTD.htm?4/36/4683\">",
"     table 2",
"    </a>",
"    ). For DLCO values that are close to the lower limit of the normal range (eg, between 75 and 80 percent of predicted), the correlation with the presence or absence of clinical disease is less well-defined. The severity cutpoints of 40 to 60 percent are also imprecise, and the degree of associated clinical impairment appears to depend on the underlying disease process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient had a previous DLCO test of high quality in the same laboratory, the change in DLCO from the baseline or most recent DLCO (rather than the percent predicted) should be used to determine progression or regression of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/37\">",
"     37",
"    </a>",
"    ]. In pulmonary function laboratories with excellent quality control procedures, a change in absolute value greater than 4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg is outside the range of measurement \"noise\" (ie, the short-term, within-subject variability) (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Quality problems'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Current smokers have DLCOs significantly lower than nonsmokers, a factor that may be important to integrate into clinical interpretations, such as when estimating the degree of impairment secondary to asbestos exposure. Since the reduction of DLCO partially resolves after smoking cessation, the reduction of DLCO in current smokers cannot be attributed entirely to emphysema, and can be influenced by increased carboxyhemoglobin levels (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Carboxyhemoglobin'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disorders associated with an abnormal DLCO are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef73588 \" href=\"UTD.htm?3/38/3692\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Low DLCO with obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term cigarette smokers, a low DLCO with airways obstruction is usually due to emphysema. The subsequent rate of decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    is predicted by the degree of airflow obstruction and airway hyperreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/41\">",
"     41",
"    </a>",
"    ]. There is little evidence that a lower DLCO predicts increased morbidity or mortality from COPD (for a given baseline FEV",
"    <sub>",
"     1",
"    </sub>",
"    and degree of airway hyperreactivity).",
"   </p>",
"   <p>",
"    In COPD, the loss of DLCO usually occurs after the decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    , so that the percent predicted DLCO is usually higher than the percent predicted FEV",
"    <sub>",
"     1",
"    </sub>",
"    . If the DLCO is severely reduced with only mild airflow obstruction, causes of a low DLCO other than emphysema should be considered.",
"   </p>",
"   <p>",
"    Cystic fibrosis and alpha-1 antitrypsin deficiency should be considered in children and young adults with obstruction and a low DLCO. This pattern can also be seen in adults with bronchiolitis obliterans, bronchiectasis, and lymphangioleiomyomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Low DLCO with restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduced DLCO in patients with low lung volumes, indicating a restrictive pattern, suggests interstitial lung disease or pneumonitis. There is often mild airflow obstruction superimposed on the restriction, due to narrowing of the terminal airways by the interstitial process. This pattern of low DLCO plus both restriction and \"small airways\" obstruction is also seen in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sarcoidosis (stage II through IV)",
"     </li>",
"     <li>",
"      Asbestosis",
"     </li>",
"     <li>",
"      Miliary tuberculosis",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with heart failure, restriction and low DLCO are due to alveolar filling, while mild obstruction can be due to edema of small airways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Low DLCO with normal spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders to consider with an isolated decrease in DLCO include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary vascular disease (mild to severe decrease in DLCO), such as chronic recurrent pulmonary emboli, idiopathic pulmonary arterial hypertension, and pulmonary vascular involvement with connective tissue diseases and vasculitides such as systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"       \"Overview of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early interstitial lung disease (mild to moderate decrease in DLCO) before the vital capacity falls below the lower limit of the normal range.",
"     </li>",
"     <li>",
"      Anemia (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Anemia'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      An increased carboxyhemoglobin level (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Carboxyhemoglobin'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Increased DLCO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders to consider when the DLCO is above the normal range (typically greater than 140 percent of predicted) include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/6,43,44\">",
"     6,43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe obesity",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Polycythemia",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage",
"     </li>",
"     <li>",
"      Left-to-right intracardiac shunting",
"     </li>",
"     <li>",
"      Mild left heart failure (due to increased pulmonary capillary blood volume)",
"     </li>",
"     <li>",
"      Exercise just prior to the test session (due to increased cardiac output)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of course, laboratory errors such as entry of a low height or age, a leak around the mouthpiece, or an inaccurate CO analyzer, should also be considered (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Quality problems'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia reduces the DLCO. As an example, loss of blood from a healthy adult male leading to a decrease in hemoglobin from 16 down to 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    results in a decline in DLCO from 100 percent to 75 percent of predicted. This will be reported as a mildly abnormal DLCO. Therefore, if the patient is at risk for anemia or known to have anemia, the laboratory should obtain a recent hemoglobin value in order to report both the adjusted and the measured DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adjusted value estimates the DLCO if the patient were to be transfused to a normal hemoglobin (14.6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for adult men and 13.4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for women and for children under age 15). The DLCO falls about 9 percent during menstruation, although this effect is not completely explained by changes in hemoglobin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Carboxyhemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carboxyhemoglobin (COHb) level may be elevated if the patient was smoking just prior to the DLCO measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/38\">",
"     38",
"    </a>",
"    ]. An increase of each 1 percent in COHb results in a 1 percent decrease in the measured DLCO. Most laboratories merely ask the patient to refrain from smoking for four hours prior to the test, but do not measure COHb or adjust the measured DLCO for the small effect of an increased CO \"back pressure\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/46\">",
"     46",
"    </a>",
"    ]. Smoking cessation results in a mean DLCO increase of 2 to 4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     High altitude",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the laboratory is located at high altitude, the ambient, alveolar, and arterial oxygen concentrations are lower than at sea level. This results in less competition for CO binding to hemoglobin, increased CO uptake, and higher measured DLCO compared to a test done at sea level.",
"   </p>",
"   <p>",
"    Patients living at high altitude also have slightly higher hemoglobin levels, resulting in increased DLCO values. In order to correct for these effects, laboratories at higher altitudes may select to use the DLCO reference equations from the study of Crapo and coworkers, which was performed at high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     VOLUME CORRECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many laboratories also report a DLCO \"corrected\" for the measured lung volume, ie,",
"    <span class=\"nowrap\">",
"     DLCO/VA,",
"    </span>",
"    where VA is the alveolar volume during the breathhold maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/48\">",
"     48",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     DLCO/VA",
"    </span>",
"    is not helpful in the differential diagnosis of lung volume restriction, since almost all patients with biopsy proven interstitial lung disease have low DLCO values, but many have a normal",
"    <span class=\"nowrap\">",
"     DLCO/VA",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in the",
"    <span class=\"nowrap\">",
"     DLCO/VA",
"    </span>",
"    may also be misleading during follow-up examination of interstitial lung disease, since improvements in both the DLCO and lung volumes (numerator and denominator) commonly occur during successful therapy. Consequently, we recommend against using the",
"    <span class=\"nowrap\">",
"     DLCO/VA",
"    </span>",
"    ratio when interpreting the results of a DLCO test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     QUALITY PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, despite the high clinical volume and value of DLCO tests, the quality of reported DLCO results remains a problem for many pulmonary function laboratories. When healthy subjects are tested in different laboratories, the results (both absolute DLCO and percent predicted) vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Even when tested in the same laboratory a few days later, DLCO results from healthy subjects may vary as much as 8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg, although variance from the best laboratories is about 2 to 4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The short-term variability of DLCO in patients with lung disease (without interventions) is likely to be somewhat larger than that of healthy \"biologic controls.\" Each laboratory should test the DLCO of at least one healthy technician every Monday morning, and compare it to their previous results. When interpreting the significance of a reported change in DLCO, it is prudent to ask the laboratory for recent results of repeatability studies.",
"   </p>",
"   <p>",
"    Although standards committees from the American Thoracic Society and the European Respiratory Society have published DLCO instrument and test methodology standards [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7400/abstract/1,2,54\">",
"     1,2,54",
"    </a>",
"    ], no third-party testing of commercially available DLCO instruments has been done to see which models meet these standards. DLCO results are very sensitive to errors in CO analyzers, which drift over time if not closely maintained. In 2003, a great advance in DLCO quality was made with the commercial availability of a device to validate DLCO results using calibration gases, syringes, valves, and software (Hans Rudolph, Kansas City, MO).",
"   </p>",
"   <p>",
"    A variety of reference equations are used, resulting in wide variations in the predicted DLCO for the same patient tested in different laboratories. The American Thoracic Society has not yet made recommendations for a standardized set of DLCO reference equations, and those recommended by the European Respiratory Society for adults are from studies that did not conform to current American Thoracic Society recommendations regarding instruments and test methods. Many computer programs erroneously use 80 percent of predicted as the lower limit of the normal range instead of the 5th percentile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DLCO can narrow the differential diagnosis of airway obstruction that persists after inhaling a bronchodilator. The DLCO decreases in patients with emphysema, whereas it tends to be normal or high in patients with asthma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Obstructive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The DLCO can also narrow the differential diagnosis of restrictive lung disease. A low DLCO combined with reduced lung volumes suggests interstitial lung disease. In contrast, a normal DLCO associated with low lung volumes suggests an extrapulmonary cause of the restriction, such as obesity, pleural effusion, pleural thickening, neuromuscular weakness, or kyphoscoliosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Restrictive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low DLCO predicts oxygen desaturation during exercise and long-term outcome of lung volume reduction surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Need for oxygen therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Prior to lung resection surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders to consider when an isolated decrease in the DLCO is detected include the pulmonary vascular diseases, early interstitial lung disease, anemia, and carboxyhemoglobinemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Low DLCO with normal spirometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Change in the DLCO is a good index of disease progression or response to therapy. A change greater than 4",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per mmHg is unlikely to be \"noise\" in good PFT labs and usually indicates a clinically significant difference. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       DLCO/VA",
"      </span>",
"      is commonly misleading and should be ignored. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Volume correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/1\">",
"      Single breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/2\">",
"      Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/3\">",
"      Crapo RO, Jensen RL, Wanger JS. Single-breath carbon monoxide diffusing capacity. Clin Chest Med 2001; 22:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/4\">",
"      Morrison NJ, Abboud RT, Ramadan F, et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am Rev Respir Dis 1989; 139:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/5\">",
"      Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 1991; 4:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/6\">",
"      Saydain G, Beck KC, Decker PA, et al. Clinical significance of elevated diffusing capacity. Chest 2004; 125:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/7\">",
"      Merkus PJ, Govaere ES, Hop WH, et al. Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol 2004; 37:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/8\">",
"      Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME. The diffusing capacity in adult cystic fibrosis. Respir Med 2003; 97:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/9\">",
"      Zompatori M, Calabr&ograve; E, Chetta A, et al. [Chronic hypersensitivity pneumonitis or idiopathic pulmonary fibrosis? Diagnostic role of high resolution Computed Tomography (HRCT)]. Radiol Med 2003; 106:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/10\">",
"      Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/11\">",
"      do Pico GA, Wiley AL Jr, Rao P, Dickie HA. Pulmonary reaction to upper mantle radiation therapy for Hodgkin's disease. Chest 1979; 75:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/12\">",
"      Theuws JC, Muller SH, Seppenwoolde Y, et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. J Clin Oncol 1999; 17:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/13\">",
"      Luursema PB, Star-Kroesen MA, van der Mark TW, et al. Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its components. Am Rev Respir Dis 1983; 128:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/14\">",
"      Crawford SW, Pepe M, Lin D, et al. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995; 152:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/15\">",
"      Ewert R, Opitz C, Wensel R, et al. Abnormalities of pulmonary diffusion capacity in long-term survivors after kidney transplantation. Chest 2002; 122:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/16\">",
"      Mitchell DM, Fleming J, Pinching AJ, et al. Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients. Am Rev Respir Dis 1992; 146:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/17\">",
"      Nieman RB, Fleming J, Coker RJ, et al. Reduced carbon monoxide transfer factor (TLCO) in human immunodeficiency virus type I (HIV-I) infection as a predictor for faster progression to AIDS. Thorax 1993; 48:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/18\">",
"      Schachter LM, Dixon J, Pierce RJ, O'Brien P. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003; 123:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/19\">",
"      Schwartz DA, Van Fossen DS, Davis CS, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/20\">",
"      Steenhuis LH, Groen HJ, Ko&euml;ter GH, van der Mark TW. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J 2000; 16:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/21\">",
"      Fernandez-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, et al. Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). Chest 1983; 83:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/22\">",
"      Tashkin DP, Clements PJ, Wright RS, et al. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. Chest 1994; 105:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/23\">",
"      Hills EA, Geary M. Membrane diffusing capacity and pulmonary capillary volume in rheumatoid disease. Thorax 1980; 35:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/24\">",
"      Song&uuml;r N, Song&uuml;r Y, T&uuml;z&uuml;n M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003; 37:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/25\">",
"      Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/26\">",
"      Wang JS. Relationship of carbon monoxide pulmonary diffusing capacity to postoperative cardiopulmonary complications in patients undergoing pneumonectomy. Kaohsiung J Med Sci 2003; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/27\">",
"      Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest 2003; 123:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/28\">",
"      Beckles MA, Spiro SG, Colice GL, et al. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 2003; 123:105S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/29\">",
"      Iwasaki A, Yosinaga Y, Kawahara K, Shirakusa T. Evaluation of lung volume reduction surgery (LVRS) based on long-term survival rate analysis. Thorac Cardiovasc Surg 2003; 51:277.",
"     </a>",
"    </li>",
"    <li>",
"     American Medical Association. Guides to the Evaluation of Permanent Impairment, 5th ed, American Medical Association, Chicago, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/31\">",
"      Evaluation of impairment/disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/32\">",
"      Sue DY, Oren A, Hansen JE, Wasserman K. Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. N Engl J Med 1987; 316:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/33\">",
"      Hadeli KO, Siegel EM, Sherrill DL, et al. Predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest 2001; 120:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/34\">",
"      Mohsenifar Z, Lee SM, Diaz P, et al. Single-breath diffusing capacity of the lung for carbon monoxide: a predictor of PaO2, maximum work rate, and walking distance in patients with emphysema. Chest 2003; 123:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/35\">",
"      Jensen RL, Crapo RO. Diffusing capacity: how to get it right. Respir Care 2003; 48:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/36\">",
"      Punjabi NM, Shade D, Patel AM, Wise RA. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003; 123:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/37\">",
"      Drummond MB, Schwartz PF, Duggan WT, et al. Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease. Am J Respir Crit Care Med 2008; 178:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/38\">",
"      Sansores RH, Pare PD, Abboud RT. Acute effect of cigarette smoking on the carbon monoxide diffusing capacity of the lung. Am Rev Respir Dis 1992; 146:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/39\">",
"      Sansores RH, Pare P, Abboud RT. Effect of smoking cessation on pulmonary carbon monoxide diffusing capacity and capillary blood volume. Am Rev Respir Dis 1992; 146:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/40\">",
"      Miller A, Thornton JC, Warshaw R, et al. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis 1983; 127:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/41\">",
"      Rijcken B, Schouten JP, Xu X, et al. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995; 151:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/42\">",
"      Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/43\">",
"      Coulter TD, Stoller JK. What causes an elevated diffusing capacity? Respir Care 2000; 45:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/44\">",
"      Stewart RI. Carbon monoxide diffusing capacity in asthmatic patients with mild airflow limitation. Chest 1988; 94:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/45\">",
"      Sansores RH, Abboud RT, Kennell C, Haynes N. The effect of menstruation on the pulmonary carbon monoxide diffusing capacity. Am J Respir Crit Care Med 1995; 152:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/46\">",
"      Graham BL, Mink JT, Cotton DJ. Effects of increasing carboxyhemoglobin on the single breath carbon monoxide diffusing capacity. Am J Respir Crit Care Med 2002; 165:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/47\">",
"      Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/48\">",
"      Johnson DC. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume. Respir Med 2000; 94:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/49\">",
"      Kanengiser LC, Rapoport DM, Epstein H, Goldring RM. Volume adjustment of mechanics and diffusion in interstitial lung disease. Lack of clinical relevance. Chest 1989; 96:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/50\">",
"      Kangalee KM, Abboud RT. Interlaboratory and intralaboratory variability in pulmonary function testing. A 13-year study using a normal biologic control. Chest 1992; 101:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/51\">",
"      Mushtaq M, Hayton R, Watts T, et al. An audit of pulmonary function laboratories in the West Midlands. Respir Med 1995; 89:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/52\">",
"      Hathaway EH, Tashkin DP, Simmons MS. Intraindividual variability in serial measurements of DLCO and alveolar volume over one year in eight healthy subjects using three independent measuring systems. Am Rev Respir Dis 1989; 140:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/53\">",
"      Robson AG, Innes JA. Short term variability of single breath carbon monoxide transfer factor. Thorax 2001; 56:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7400/abstract/54\">",
"      Cramer D. Standardization of the measurement of transfer factor. Eur Respir J 1993; 6:1577.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6972 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7400=[""].join("\n");
var outline_f7_14_7400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Obstructive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Restrictive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prior to lung resection surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Disability evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Need for oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      METHODOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Low DLCO with obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Low DLCO with restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Low DLCO with normal spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Increased DLCO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Carboxyhemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      High altitude",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      VOLUME CORRECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      QUALITY PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6972|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/35/9790\" title=\"figure 1\">",
"      Single breath DLCO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/8/4235\" title=\"table 1\">",
"      Indications for DLCO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/36/4683\" title=\"table 2\">",
"      Severity classification DLCO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/38/3692\" title=\"table 3\">",
"      Interpretation of DLCO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=related_link\">",
"      Evaluation of pulmonary disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7401="Pubertal development and gonadal function in survivors of childhood cancer";
var content_f7_14_7401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pubertal development and gonadal function in survivors of childhood cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7401/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7401/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7401/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7401/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7401/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7401/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/14/7401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing numbers of children and adults are survivors of childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One estimate suggests that 1 in every 900 adults is a survivor of childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. These survivors are subject to long-term complications of tumor or its therapy, including endocrinologic abnormalities.",
"   </p>",
"   <p>",
"    The most common endocrinologic abnormalities in survivors of childhood cancer are growth hormone (GH) deficiency and hypothyroidism (either central or primary), followed by complications that affect pubertal development and gonadal function.",
"   </p>",
"   <p>",
"    Complications of pubertal development and gonadal function in survivors of childhood cancer are reviewed here. Endocrine surveillance, GH deficiency, and hypothyroidism after childhood cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H843981150\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal development, secondary sexual characteristics begin to develop during puberty in response to hormonal secretion by the gonads. The testes produce testosterone, and the ovaries produce estrogen and progesterone in response to the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the pituitary gland. The pituitary gland produces LH and FSH in response to pulsatile release of gonadotropin releasing hormone (GnRH) from the hypothalamus. The hypothalamic stimulus for puberty, which is not fully understood, is actively inhibited between six months of age and the usual age of onset of puberty. The normal sequence and timing of pubertal events are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In childhood cancer survivors, alterations in the normal pubertal process may occur either due to the underlying tumor or its treatment, and are classified into four groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early onset (precocious) or rapid tempo of puberty",
"     </li>",
"     <li>",
"      Normally timed puberty in the presence of slow linear growth",
"     </li>",
"     <li>",
"      Delayed, absent, or interrupted puberty",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type of pubertal problem in the individual cancer survivor depends upon the tumor location and the type of therapy with which it was treated (",
"    <a class=\"graphic graphic_table graphicRef77692 \" href=\"UTD.htm?40/45/41691\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRECOCIOUS OR RAPID PUBERTY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784557048\">",
"    <span class=\"h2\">",
"     Precocious puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with precocious puberty begin pubertal development at an earlier age than is expected based on established normal standards. In most studies, pubertal milestones are attained at ages that describe a normal distribution with a standard deviation of approximately one year. Precocious puberty is defined as entering puberty more than 2.5 to 3 standard deviations (SD) earlier than average. Thus, the precocious puberty is clinically diagnosed as the onset of secondary sexual development before age eight years in girls and before age nine years in boys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The same guidelines for defining precocious puberty are used for survivors of childhood cancer. Precocious puberty occurs in childhood cancer survivors who have lost inhibition of hypothalamic GnRH release as a result of tumor presence (eg,",
"    <span class=\"nowrap\">",
"     hypothalamic/optic",
"    </span>",
"    pathway glioma), raised intracranial pressure, cranial surgery, or cranial radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. Cranial irradiation leads to earlier menarche in girls, but is less likely to cause early puberty in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the childhood cancer survivor with precocious puberty includes a bone age and measurement of LH, FSH, and estradiol or testosterone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The radiograph of the left hand and wrist shows bone age that is advanced compared with chronologic age in most children with precocious puberty; however, the bone age may be consistent with chronologic age in a child who has concurrent growth hormone deficiency or hypothyroidism and has not undergone a growth spurt [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The serum concentrations of LH, FSH, estradiol, and testosterone are at pubertal levels, which would be abnormally high for the chronologic age of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rapid puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who have received cranial irradiation, puberty may start at a normal or an early age, and then advance rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/4-6,13\">",
"     4-6,13",
"    </a>",
"    ]. Rapid tempo of puberty is defined by progression from breast buds to menarche in 18 months or less (the entire course of normal puberty typically occurs in 24 to 30 months), or by increase in testicular volume of 10 mL in 12 months (normally occurs in 24 months). Lower doses of cranial radiation (less than 30 Gy) are more likely to cause rapid tempo of puberty or precocious puberty. Higher doses are more likely to cause hypothalamic GnRH deficiency and therefore gonadotropin deficiency (or precocious onset puberty that progresses to gonadotropin deficiency), which results in absent puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of rapid tempo of puberty is short adult height as early bony maturation causes the child to lose one to three years of height growth. Rapid puberty probably is caused by loss of inhibition of hypothalamic GnRH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood cancer survivors who have begun the pubertal process should have regular assessment of their pubertal development to determine whether it is progressing at an accelerated pace. A bone age radiograph every six months can be a useful tool in monitoring tempo of puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784557144\">",
"    <span class=\"h2\">",
"     Treatment with GnRH analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH analogs are the most effective treatments for precocious puberty, rapid tempo puberty, or normally timed puberty that is inappropriate for height [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/4,13,15\">",
"     4,13,15",
"    </a>",
"    ]. GnRH analogs suppress LH and FSH release from the pituitary gland through the provision of a steady rather than a pulsatile level of GnRH; the pituitary gland stops responding to GnRH when GnRH concentrations are steady or unchanging. The use of GnRH analogs to delay pubertal progression optimizes adult height potential by permitting the child to grow taller without rapid change in bone maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4889?source=see_link&amp;anchor=H23809007#H23809007\">",
"     \"Treatment of precocious puberty\", section on 'GnRH agonist treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with GnRH analogs should be prescribed and monitored by a pediatric endocrinologist. GnRH analogs can be administered daily as a subcutaneous injection, every four weeks, three monthly, or yearly in a sustained or depot preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. GnRH analog therapy is usually continued until patients attain the third percentile for adult height: 152 cm (60 inches) in girls and 162 cm (64 inches) in boys.",
"   </p>",
"   <p>",
"    Children who are treated with GnRH analogs should be revaluated by the endocrinologist every three to six months. A short GnRH test can document continued pubertal suppression. Many children have a tendency to gain weight during GnRH analog therapy. One in 10 children may develop a lump at the depot injection site. In addition to causing pain and anxiety, recurrent lumps can sequester the medication, resulting in loss of pubertal suppression. Children who have this complication may need to switch from depot GnRH to daily injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PUBERTY AND SLOW LINEAR GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally timed puberty in the face of slow linear growth may be observed during chemotherapy, after cranial surgery, or after cranial radiation causing growth hormone deficiency or central hypothyroidism. Slow linear growth is defined by a growth rate of less than 5 cm per year or the failure for a girl to have a growth spurt within six months after the appearance of breast buds.",
"   </p>",
"   <p>",
"    Although it is not technically a pubertal problem, normally timed puberty in children who have slow linear growth (eg, as a result of growth hormone [GH] deficiency or hypothyroidism) can compromise the child's or adolescent's adult height because bone maturity will be reached before the child's growth potential is fulfilled [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood cancer survivors should undergo regular height measurement and determination of growth velocity. Those who have slow linear growth should be evaluated for nutritional, GH, or thyroid hormone causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of growth hormone deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally timed puberty in individuals with short stature is most effectively treated with GnRH analogs as described above. (See",
"    <a class=\"local\" href=\"#H784557144\">",
"     'Treatment with GnRH analogs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DELAYED, INTERRUPTED, OR ABSENT PUBERTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed puberty is defined by the absence or incomplete development of secondary sexual characteristics by an age at which 95 percent of children of that sex and culture have initiated sexual maturation. Staging of puberty usually is performed by the criteria of Tanner. Based on data from the National Center for Health Statistics, the upper 95th percentile in the United States for age for boys is 14 (testicular development being the first sign) and for girls is 12 (breast development being the first sign). The same guidelines for defining delayed puberty are used for survivors of childhood cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed onset or interrupted progression of puberty (eg, secondary amenorrhea) can occur in young people during chronic illness caused by transient hypothalamic dysfunction or as a temporary effect of GH deficiency or hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12\">",
"     12",
"    </a>",
"    ]. In children with cancer, delayed onset or progression of puberty may occur during chemotherapy or radiation therapy for leukemia, Hodgkin lymphoma or central nervous system (CNS) tumor, in posterior fossa syndrome, during a graft versus host reaction in patients who receive a hematopoietic cell transplantation, or while requiring pharmacologic steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Female survivors of CNS tumors are more likely than siblings to have onset of menarche after 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absent puberty occurs when pubertal delay or interruption persists beyond the duration of the abnormal metabolic state. Absent puberty can result from hypothalamic-pituitary injury, gonadotropin deficiency, or primary gonadal injury caused by high doses of cranial radiation for brain tumor, radiation to the gonads for testicular relapse of leukemia, or chemotherapeutic agents, such as alkylating agents, MOPP (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/16/9477?source=see_link\">",
"     Mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39862?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ), or COPP (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    , vincristine, prednisone, procarbazine), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/6,24-29\">",
"     6,24-29",
"    </a>",
"    ]. Boys are more likely than girls to experience complete hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/25\">",
"     25",
"    </a>",
"    ]. Girls are more likely to have a shortened duration of ovulatory cycles (fewer ova) and early menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth curves of all children who have been treated for cancer should be monitored closely to identify a crossing of percentile lines. Continued observation for two to three years will indicate whether the growth dysfunction is transient or permanent. The primary medical risk of delayed puberty is delayed bone mineralization.",
"   </p>",
"   <p>",
"    Breast development, pubic hair growth and distribution, and vaginal estrogenization should be monitored every six months in girls with pubertal delay. Testes size (using a Prader orchidometer), pubic hair growth and distribution, and phallus length should be monitored every six months in boys with pubertal delay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/16,30\">",
"     16,30",
"    </a>",
"    ]. The absence of progression of pubertal changes by one year after completion of cancer therapy, or by 13 years of age in girls or 14 years of age in boys, should prompt evaluation by an endocrinologist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/16,30\">",
"     16,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evaluation should include measurement of serum LH, FSH, testosterone, and inhibin B in males, and serum LH, FSH, estradiol, and anti-m&uuml;llerian hormone in females in children with delayed or interrupted progression of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/23,31-37\">",
"     23,31-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents with delayed or interrupted puberty should be treated with daily calcium (1500 mg elemental calcium) and vitamin D supplements (1000 international units) to improve bone mineralization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"     \"Calcium requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of estrogen or testosterone therapy in a cancer survivor should not be initiated without careful attention to the child's growth pattern. Replacement of pubertal hormones in a short or slowly growing adolescent can cause fusion of bony growth centers and shorter-than-expected adult height. Such therapy should be provided only in coordination with the pediatric endocrinologist after assessment of growth potential and treatment of GH or thyroid deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of sex steroid therapy in a short adolescent may be delayed until age 15 years to permit response to GH or thyroid hormone therapy and taller adult height. In short adolescents with delayed puberty, a few years of therapy with low-dose sex steroid therapy is preferable to full replacement. Such doses simulate the sex steroid levels observed in the first year or so of puberty and are less likely than full sex steroid replacement to cause inappropriate maturation of bone age. Of note, delay of pubertal development can be associated with delayed psychosexual development [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Girls can be treated with Premarin&reg; 0.3 mg every other day or ethinyl estradiol 5 mcg daily (one-quarter of a 20 mcg tablet) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/39\">",
"       39",
"      </a>",
"      ]. Menstrual spotting can be treated with medroxyprogesterone 10 mg PO per day for 10 days followed by resumption of low-dose estrogen.",
"     </li>",
"     <li>",
"      Boys can be treated with 45 or 50 mg per m2 testosterone enanthate injected intramuscularly each month, or topical androgen can be administered by patch or gel [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/40\">",
"       40",
"      </a>",
"      ]. The gel dose can be adjusted to achieve the desired serum testosterone concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both boys and girls who are near an acceptable adult height may benefit from a gradual increase in hormone replacement therapy to the full replacement dose if there has been no sex steroid production in recent months. The increase to full replacement should take place in one- to three-month steps depending on adequacy of stature to permit adjustment to the hormonal effects.",
"   </p>",
"   <p>",
"    Full hormone replacement of adolescent girls who have reached their adult height is easily achieved with a standard birth control pill 28-day packet. Boys who have attained their adult height can be treated with testosterone 200 mg injected intramuscularly every two weeks, with androgen patches, or with topical testosterone gel therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infertility is defined as the inability to conceive or maintain a pregnancy after 12 months of trying. Infertility in cancer survivors may result from cancer therapy that has directly affected the gonads (primary hypogonadism). Infertility in cancer survivors also may be caused by hypothalamic deficiency rather than germ cell loss (secondary hypogonadism). Prepubertal children may be less susceptible to the gonadal effects of chemotherapy than those in whom puberty has begun. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary hypogonadism in cancer survivors can be caused by irradiation to the testes for leukemia recurrence, pelvic irradiation for solid tumors, irradiation for Hodgkin lymphoma, total body irradiation for bone marrow transplant, or chemotherapies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12,25,31,32,36,41-50\">",
"     12,25,31,32,36,41-50",
"    </a>",
"    ]. Chemotherapeutic agents that have been associated with infertility include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/16/9477?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/9/35989?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/19/7479?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39862?source=see_link\">",
"     procarbazine",
"    </a>",
"    , nitrosourea, platinum, nitrogen mustard, and combinations such as MOPP (Mechlorethamine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    , procarbazine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and COPP (Cyclophosphamide, vincristine, prednisone, procarbazine) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12,27,51-53\">",
"     12,27,51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H8#H8\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sperm production is more sensitive to radiation or chemotherapy-induced injury than are ova because ova are resting in meiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12\">",
"     12",
"    </a>",
"    ]. In one review, 17 men treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in childhood had oligospermia or azoospermia in adulthood, indicating that exposure prior to puberty was not protective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/52\">",
"     52",
"    </a>",
"    ]. Radiation doses to the testes in excess of 250 cGy may lead to infertility; in contrast, the ovaries may still function after more than 1000 cGy. Decrease in sperm production results in decreased inhibin and increased FSH, whereas loss of ova results in a shorter reproduction period (premature menopause) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 1067 women who were at least five-year survivors of cancer diagnosed before age 20 and who were still menstruating at age 21 were interviewed; self-reported status in survivors was compared with that of 1599 control women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/54\">",
"     54",
"    </a>",
"    ]. Cancer survivors diagnosed between ages 13 and 19 years had a risk of menopause four times greater than control women during the ages of 21 to 25; by age 31, the risk was eight times greater (42 versus 5 percent). The relative risk of menopause in the early 20s was greatest for those treated with both radiation below the diaphragm and alkylating agents (27), but remained increased for those treated with either modality alone (9.2 for alkylating agents and 3.7 for radiation therapy). Another study examined 182 long-term survivors of ALL at the average age of 22 years who reported one-quarter of the expected fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/55\">",
"     55",
"    </a>",
"    ]. Significant fertility deficits were noted compared to their siblings if cranial radiation therapy was given at any dose around the time of menarche.",
"   </p>",
"   <p>",
"    Women who have undergone bone marrow transplantation have increased risk of spontaneous abortion and preterm labor, with no apparent increased risk of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/56\">",
"     56",
"    </a>",
"    ]. The uterus and ovaries have reduced volume by ultrasound, and uterine blood flow may be impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Girls who have partial primary hypogonadism may have gradual progression of breast development and menarche with irregular menstrual periods. Boys who have partial primary hypogonadism may have progression of virilization including phallic growth and development of pubic and facial hair, but have small testes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/58\">",
"     58",
"    </a>",
"    ]. This clinical picture suggests sustained testosterone production but loss of spermatogenesis. LH may be normal with a low normal testosterone level; however, FSH is usually elevated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6632140\">",
"    <span class=\"h2\">",
"     Preservation of fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing research is being performed to develop ways to increase fertility preservation in childhood cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/47,59-61\">",
"     47,59-61",
"    </a>",
"    ]. Pharmacologic suppression of gonadal activity during cancer therapy does not appear to mitigate the injury to germ cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/14\">",
"     14",
"    </a>",
"    ]. The evidence base for possible benefit is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=see_link\">",
"     \"Effects of cytotoxic agents on gonadal function in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of infertility may involve hormone therapy and the services of specialists in andrology and gynecology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/29,45,62,63\">",
"     29,45,62,63",
"    </a>",
"    ]. Treatment with GnRH or LH and FSH may lead to recovery of sperm production or ovulation in patients whose infertility is caused by hypothalamic deficiency. In those with primary hypogonadism, insemination or in vitro fertilization with donor oocytes may lead to successful conception. The ability to fertilize an ovum or to safely carry a pregnancy to term must be assessed in view of the man or woman's medical history [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7401/abstract/45,64-67\">",
"     45,64-67",
"    </a>",
"    ]. Adoption may be an important alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=see_link\">",
"     \"Adoption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=see_link\">",
"       \"Patient information: Preserving fertility after cancer treatment in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784557010\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications in childhood cancer survivors include pubertal and reproductive problems, which can be classified into the following four groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early onset (precocious) or rapid tempo of puberty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with precocious puberty begin pubertal development at a much earlier than expected normal age, due to the loss of inhibition of hypothalamic GnRH release as a result of tumor presence, raised intracranial pressure, cranial surgery, or cranial radiation. In these patients, the evaluation includes a bone age and measurements of luteinizing hormone (LH), follicle stimulating hormone (FSH), and estradiol or testosterone. (See",
"      <a class=\"local\" href=\"#H784557048\">",
"       'Precocious puberty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with rapid puberty tempo begin puberty at a normal or an early age, which advances rapidly. Rapid puberty is most often a complication of cranial irradiation and results in short adult height. Childhood cancer survivors who have begun the pubertal process should have regular assessment of their pubertal development to determine whether it is progressing at an accelerated pace. A bone age radiograph every six months can be a useful tool in monitoring tempo of puberty and growth. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Rapid puberty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GnRH analogs are the most effective treatments for precocious puberty, rapid tempo puberty, or normally timed puberty that is inappropriate for height. (See",
"      <a class=\"local\" href=\"#H784557144\">",
"       'Treatment with GnRH analogs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normally timed puberty in the presence of slow linear growth may be observed during chemotherapy, after cranial surgery, or after cranial radiation causing growth hormone deficiency or central hypothyroidism. Slow linear growth is defined by a growth rate of less than 5 cm per year or the failure for a girl to have a growth spurt within six months after the appearance of breast buds. Patients who have slow linear growth during puberty should be evaluated for nutritional, growth hormone, or thyroid hormone causes. For these patients, GnRH therapy is the most effective treatment, in addition to treating the cause of the slowed growth. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Puberty and slow linear growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delayed, absent, or interrupted puberty is defined by the absence or incomplete development of secondary sexual characteristics by an age at which 95 percent of normal children of that sex and culture have initiated sexual maturation. Childhood cancer survivors may have delayed, absent, or interrupted puberty due to chemotherapy or radiation therapy. Evaluation should include assessment of growth, and laboratory testing in males of serum LH, FSH, testosterone, and inhibin B, and in females, serum LH, FSH, estradiol, and anti-m&uuml;llerian hormone. Treatment initially consists of supplemental calcium and vitamin D to improve bone mineralization. Hormonal therapy (eg, estrogen or testosterone) may be provided after consultation with a pediatric endocrinologist and assessment of growth potential and treatment of growth hormone or thyroid deficiencies. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Delayed, interrupted, or absent puberty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infertility is defined as the inability to conceive or maintain a pregnancy after 12 months of trying. In childhood cancer survivors, infertility is caused by damage to the gonads from either radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapeutic agents. Treatment of infertility may involve hormone therapy or assisted reproductive services, such as artificial insemination or in vitro fertilization. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute. Bethesda, MD. file://seer.cancer.gov/csr/1975_2007/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/2\">",
"      Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010; 174:840.",
"     </a>",
"    </li>",
"    <li>",
"     Armenian SH, Meadows AT, Ghatia S. Late effects of childhood cancer and its treatment. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.1368.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/4\">",
"      Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer 2004; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/5\">",
"      Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/6\">",
"      Chow EJ, Friedman DL, Yasui Y, et al. Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2008; 50:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/7\">",
"      Rohrer TR, Beck JD, Grabenbauer GG, et al. Late endocrine sequelae after radiotherapy of pediatric brain tumors are independent of tumor location. J Endocrinol Invest 2009; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/8\">",
"      Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 2009; 115:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/9\">",
"      Armstrong GT, Chow EJ, Sklar CA. Alterations in pubertal timing following therapy for childhood malignancies. Endocr Dev 2009; 15:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/10\">",
"      Fouladi M, Wallace D, Langston JW, et al. Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 2003; 97:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/11\">",
"      Noorda EM, Somers R, van Leeuwen FE, et al. Adult height and age at menarche in childhood cancer survivors. Eur J Cancer 2001; 37:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/12\">",
"      Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/13\">",
"      Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003; 88:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/14\">",
"      Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG 2002; 109:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/15\">",
"      Bozzola M, Albanese A, Butler GE, et al. Unresolved problems in optimal therapy of pubertal disorders in oncological and bone marrow transplanted patients. J Pediatr Endocrinol Metab 2001; 14 Suppl 2:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/16\">",
"      Rose SR. Endocrinopathies after childhood cancer. Endocrinologist 2003; 13:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/17\">",
"      Lee PA, Houk CP. Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty. Treat Endocrinol 2006; 5:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/18\">",
"      Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/19\">",
"      Couto-Silva AC, Brauner R, Adan LF. [Endocrine sequelae after radiotherapy in childhood and adolescence]. Arq Bras Endocrinol Metabol 2005; 49:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/20\">",
"      Darzy KH, Shalet SM. Hypopituitarism after cranial irradiation. J Endocrinol Invest 2005; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/21\">",
"      Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004; 14 Suppl A:S118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/22\">",
"      Miyoshi Y, Ohta H, Hashii Y, et al. Endocrinological analysis of 122 Japanese childhood cancer survivors in a single hospital. Endocr J 2008; 55:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/23\">",
"      Krawczuk-Rybak M, Solarz E, Wojtkowska M, et al. [Gonadal function in young men after the treatment for Hodgkin lymphoma]. Pediatr Endocrinol Diabetes Metab 2009; 15:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/24\">",
"      Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2005; 44:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/25\">",
"      Zaletel LZ, Bratanic N, Jereb B. Gonadal function in patients treated for leukemia in childhood. Leuk Lymphoma 2004; 45:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/26\">",
"      Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003; 97:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/27\">",
"      van den Berg H, Furstner F, van den Bos C, Behrendt H. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2004; 42:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/28\">",
"      Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/29\">",
"      Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007; 19:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/30\">",
"      Meacham LR, Ghim TT, Crocker IR, et al. Systematic approach for detection of endocrine disorders in children treated for brain tumors. Med Pediatr Oncol 1997; 29:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/31\">",
"      van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009; 52:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/32\">",
"      Woodruff TK. The Oncofertility Consortium--addressing fertility in young people with cancer. Nat Rev Clin Oncol 2010; 7:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/33\">",
"      Rafsanjani KA, Faranoush M, Hedayatiasl AA, Vossough P. Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran. Saudi Med J 2007; 28:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/34\">",
"      Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol 2010; 35:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/35\">",
"      Romerius P, St&aring;hl O, Mo&euml;ll C, et al. Hypogonadism risk in men treated for childhood cancer. J Clin Endocrinol Metab 2009; 94:4180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/36\">",
"      Johnston RJ, Wallace WH. Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatr Blood Cancer 2009; 53:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/37\">",
"      Rendtorff R, Hohmann C, Reinmuth S, et al. Hormone and Sperm Analyses after Chemo- and Radiotherapy in Childhood and Adolescence. Klin Padiatr 2010; 222:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/38\">",
"      Dieluweit U, Debatin KM, Grabow D, et al. Social outcomes of long-term survivors of adolescent cancer. Psychooncology 2010; 19:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/39\">",
"      Rose SR. Induction of puberty in female hypogonadism. Endocrinologist 1996; 6:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/40\">",
"      McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/41\">",
"      Shalet SM, Didi M, Ogilvy-Stuart AL, et al. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol (Oxf) 1995; 42:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/42\">",
"      Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr 1997; 130:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/43\">",
"      Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996; 27:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/44\">",
"      Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000; 17:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/45\">",
"      Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst 2006; 98:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/46\">",
"      Schuck A, Hamelmann V, Br&auml;mswig JH, et al. Ovarian function following pelvic irradiation in prepubertal and pubertal girls and young adult women. Strahlenther Onkol 2005; 181:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/47\">",
"      Schmidt KT, Larsen EC, Andersen CY, Andersen AN. Risk of ovarian failure and fertility preserving methods in girls and adolescents with a malignant disease. BJOG 2010; 117:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/48\">",
"      Redig AJ, Brannigan R, Stryker SJ, et al. Incorporating fertility preservation into the care of young oncology patients. Cancer 2011; 117:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/49\">",
"      Ginsberg JP. New advances in fertility preservation for pediatric cancer patients. Curr Opin Pediatr 2011; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/50\">",
"      Oktem O, Urman B. Options of fertility preservation in female cancer patients. Obstet Gynecol Surv 2010; 65:531.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders, JE. Growth and development after hematopoietic cell transplantation. Section III. Complications and their management. p.764.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/52\">",
"      Kenney LB, Laufer MR, Grant FD, et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001; 91:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/53\">",
"      Sanders JE. Growth and development after hematopoietic cell transplant in children. Bone Marrow Transplant 2008; 41:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/54\">",
"      Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992; 166:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/55\">",
"      Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 42:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/56\">",
"      Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996; 87:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/57\">",
"      Holm K, Nysom K, Brocks V, et al. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant 1999; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/58\">",
"      Papadakis V, Vlachopapadopoulou E, Van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 1999; 32:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/59\">",
"      Mitchell RT, Saunders PT, Sharpe RM, et al. Male fertility and strategies for fertility preservation following childhood cancer treatment. Endocr Dev 2009; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/60\">",
"      Sauvat F, Binart N, Poirot C, Sarnacki S. Preserving fertility in prepubertal children. Horm Res 2009; 71 Suppl 1:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/61\">",
"      Ishiguro H, Yasuda Y, Tomita Y, et al. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant 2007; 39:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/62\">",
"      Schover LR. After the deluge: the emerging landscape of childbearing potential in pediatric cancer survivors. J Natl Cancer Inst 2006; 98:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/63\">",
"      Heath JA, Stern CJ. Fertility preservation in children newly diagnosed with cancer: existing standards of practice in Australia and New Zealand. Med J Aust 2006; 185:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/64\">",
"      Sudour H, Chastagner P, Claude L, et al. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int J Radiat Oncol Biol Phys 2010; 76:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/65\">",
"      Hudson MM. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol 2010; 116:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/66\">",
"      Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7401/abstract/67\">",
"      Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2011; 17:157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6242 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7401=[""].join("\n");
var outline_f7_14_7401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H784557010\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H843981150\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRECOCIOUS OR RAPID PUBERTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784557048\">",
"      Precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rapid puberty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H784557144\">",
"      Treatment with GnRH analogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PUBERTY AND SLOW LINEAR GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DELAYED, INTERRUPTED, OR ABSENT PUBERTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6632140\">",
"      Preservation of fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H784557010\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/45/41691\" title=\"table 1\">",
"      Pubertal problems cancer surviv",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8520?source=related_link\">",
"      Adoption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13706?source=related_link\">",
"      Effects of cytotoxic agents on gonadal function in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31607?source=related_link\">",
"      Growth failure after childhood cancer: Role of growth hormone deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/7/18546?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4889?source=related_link\">",
"      Treatment of precocious puberty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7402="Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children";
var content_f7_14_7402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Elaine I Tuomanen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/14/7402/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/14/7402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (pneumococcus) is a leading cause of serious illness among children worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. Before universal infant immunization with pneumococcal conjugate vaccine in the United States,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    caused approximately 17,000 cases of invasive disease each year among children younger than five years of age, including 700 cases of meningitis and 200 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/2\">",
"     2",
"    </a>",
"    ]. It was the most frequent cause of bacteremia, bacterial pneumonia, bacterial meningitis, sinusitis, and acute otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/2\">",
"     2",
"    </a>",
"    ]. Since pneumococcal conjugate vaccine was added to the routine childhood immunization schedule in the United States, the incidence of invasive pneumococcal disease has declined by 60 to 90 percent in children younger than two years. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Efficacy and effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of pneumococcal conjugate vaccines in children will be presented here. Pneumococcal polysaccharide vaccines in children, pneumococcal vaccination in adults, and the impact of universal infant immunization with pneumococcal conjugate vaccine in the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surface capsular polysaccharide of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    provokes a type-specific protective immune response and serves as the basis for serotyping of these organisms. More than 90 different pneumococcal serotypes have been identified. Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F are the most prevalent in children, accounting for between 60 and 80 percent of infections, depending upon the area of the world. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology and pathogenesis of Streptococcus pneumoniae\", section on 'Capsule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not currently possible to include all &gt;90 serotypes in a polysaccharide or polysaccharide-conjugate vaccine. Pneumococcal polysaccharide vaccines representing subgroups of the 14 and 23 most prevalent serotypes causing invasive disease were developed in the 1970s and 1980s (PPSV14 and PPSV23, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/3\">",
"     3",
"    </a>",
"    ]. Pneumococcal polysaccharide vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polysaccharide vaccines are poorly immunogenic in children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], the age group with the highest incidence of invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. However, conjugation of an immunogenic nonpneumococcal protein (carrier protein) to individual pneumococcal polysaccharides elicits a T cell-dependent memory response and increases the effectiveness of the vaccine during the first two years of life. Carrier proteins for pneumococcal conjugate vaccines include CRM197 (a nontoxic mutant of diphtheria toxin) and OMP (the outer membrane protein complex from",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    ). Conjugate vaccines including a pneumococcal protein are in development with the goal of expanding protection beyond capsular type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONJUGATE VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal conjugate vaccines that include 7, 9, 10, 11, 13, and 15 serotypes have been developed (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). The 13-valent vaccine is used in the United States; the 10-valent vaccine is used in Europe and anticipated to be used in developing countries in the future. The potential efficacy of the 7-, 10-, 11-, and 13-valent vaccines varies depending upon the serotypes that are included (",
"    <a class=\"graphic graphic_figure graphicRef72429 \" href=\"UTD.htm?23/61/24543\">",
"     figure 1",
"    </a>",
"    ), the geographic region (",
"    <a class=\"graphic graphic_figure graphicRef64500 \" href=\"UTD.htm?31/37/32350\">",
"     figure 2",
"    </a>",
"    ), and the age, health status, and ethnicity of the vaccinees [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/6-15\">",
"     6-15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Efficacy and effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     13-valent vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar 13) has replaced the 7-valent pneumococcal conjugate vaccine (PCV7) in the routine childhood immunization schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. PCV13 is approved by the United States Food and Drug Administration (FDA) for use in children aged 6 weeks through 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. PCV13 is licensed for the prevention of invasive pneumococcal disease (IPD) caused by the 13 vaccine serotypes in children 6 weeks through 17 years of age and for the prevention of otitis media caused by the seven serotypes in PCV7 (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) in children six weeks through five years of age. A comparison of PCV13 and 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef71746 \" href=\"UTD.htm?0/43/701\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The additional six serotypes contained in PCV13 (but not in PCV7) caused 63 percent of invasive pneumococcal disease among children &lt;5 years of age in the United States during 2006 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/17\">",
"     17",
"    </a>",
"    ]. PCV13 has the potential to expand protection against acute otitis media, IPD, acute conjunctivitis, and drug-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef72429 \" href=\"UTD.htm?23/61/24543\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/18\">",
"     18",
"    </a>",
"    ]. The addition of serotype 19A is particularly compelling since it appears to be the most frequent cause of invasive pneumococcal disease (IPD) by replacement serotypes in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H9889776#H9889776\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Invasive disease caused by non-vaccine serotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Composition &ndash; Polysaccharide from the 13 vaccine serotypes (",
"      <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"       table 1",
"      </a>",
"      ) is conjugated to CRM197 (a nontoxic mutant of diphtheria toxin), with an aluminum adjuvant. PCV13 contains no thimerosal or other preservatives [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"       1",
"      </a>",
"      ]. It is supplied in a prefilled syringe that does not contain latex [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Storage/handling",
"      </span>",
"      &ndash; PCV13 should be stored at 2 to 8&ordm;C (36 to 46&ordm;F). Exposure to freezing causes irreversible loss of potency [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/21\">",
"       21",
"      </a>",
"      ]. PCV13 that has been frozen should be discarded [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     7-valent vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 7-valent pneumococcal conjugate vaccine (PCV7, Prevnar) (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) was licensed for use in the United States in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/22\">",
"     22",
"    </a>",
"    ]. PCV7 has been replaced by PCV13 for the routine immunization of infants and children in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to PCV7 and PCV13, pneumococcal conjugate vaccines that include 9, 10, 11, and 15 serotypes have been developed (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). These vaccines are not licensed in the United States, but some are used in Europe. The 15-valent vaccine is in preclinical evaluation and was immunogenic in infant monkeys [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMMUNOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentrations of IgG capsular antibodies that correlate with protection against pneumococcal disease have not been clearly defined, but are proposed to be &ge;0.35",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    one month after primary immunization as measured by ELISA, based on a pooled meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/24\">",
"     24",
"    </a>",
"    ]. This is the minimum protective concentration recommended by the World Health Organization (WHO) for assessing the efficacy of pneumococcal conjugate vaccines in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 13-valent pneumococcal conjugate vaccine (PCV13) provided comparable immunogenicity to the 7-valent pneumococcal conjugate vaccine (PCV7) for the common serotypes in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. This extension of efficacy data for PCV7 was the basis for licensure of PCV13 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, the new serotypes met the World Health Organization- proposed minimum protective concentration in most circumstances.",
"   </p>",
"   <p>",
"    Serotype-specific antibody response may be decreased by elevated levels of maternal antibody and nasopharyngeal carriage of S. pneumoniae before immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. The booster response for specific serotypes varies depending upon the immunization schedule; reduced dose schedules may not achieve protective antibody levels for all serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The clinical significance of these observations requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFICACY AND EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and effectiveness of the seven valent pneumococcal conjugate vaccine (PCV7) were demonstrated in large randomized trials before licensure and in surveillance for invasive pneumococcal disease (IPD) after licensure in the United States and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/36-47\">",
"     36-47",
"    </a>",
"    ]. The effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in protecting against invasive pneumococcal disease is inferred from randomized trials demonstrating immunogenicity comparable to that of PCV7 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/16,20,26\">",
"     16,20,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the studies of efficacy and effectiveness of pneumococcal vaccines define invasive pneumococcal disease as the isolation of pneumococcus from a normally sterile body fluid, usually blood or cerebrospinal fluid.",
"   </p>",
"   <p>",
"    In pooled analysis of six randomized controlled trials (including more than 113,000 children) conducted in Africa, Finland, the Philippines, and the United States, the efficacy of pneumococcal conjugate vaccines for prevention of IPD caused by a serotype contained in the vaccine was 80 percent (95% CI 58-90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/48\">",
"     48",
"    </a>",
"    ]. The pooled efficacy for prevention of IPD caused by all serotypes was 58 percent (95% CI 29-75 percent). Findings were similar in children with and without HIV.",
"   </p>",
"   <p>",
"    Surveillance after the introduction of PCV7 to the standard childhood immunization schedule demonstrated that the vaccine was effective in preventing IPD and providing herd immunity (ie, protection for individuals who were not vaccinated by decreasing the incidence of disease) (",
"    <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/17,41-47,49\">",
"     17,41-47,49",
"    </a>",
"    ]. In various reports, the decline in pediatric IPD (from all serotypes) among children younger than two years ranged from 60 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. A similar decline was noted in young children with sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The largest decrease was seen in pneumococcal bacteremia without a focus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/36,52-54\">",
"     36,52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decline in IPD was greatest for vaccine serotypes and vaccine-related serotypes. By 2007, only 2 percent of IPD in children was caused by serotypes included in PCV7; 64 percent was caused by serotypes included in PCV13, particularly serotype 19A [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/55\">",
"     55",
"    </a>",
"    ]. The association between the routine use of PCV7 and increased IPD caused by nonvaccine serotypes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H9889776#H9889776\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Invasive disease caused by non-vaccine serotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, PCV7 was replaced by PCV13 in 2010. Surveillance following the introduction of PCV13 demonstrated a 42 percent reduction in IPD among children hospitalized at eight children&rsquo;s hospitals compared with the average number of cases during 2007-2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/56\">",
"     56",
"    </a>",
"    ]. IPD caused by vaccine serotypes decreased by 57 percent overall. IPD caused by serotype 19A decreased by 58 percent, IPD caused by 7F decreased by 54 percent, and IPD caused by serotype 3 decreased by 68 percent. CDC surveillance after the introduction of PCV13 also indicates dramatic reduction in IPD caused by the six serotypes included in PCV13 but not in PCV7 in both vaccine recipients and adults (eg, 88 percent in children &lt;5 years and 45 to 64 percent in adults during October-December 2001 compared with 2006-2008) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of PCV7 has also been associated with decreased IPD case fatality and mortality rates, predominantly in adults &ge;65 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H3#H3\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'Impact of childhood vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pooled analysis of six randomized controlled trials of PCV (including more than 113,000 children) conducted in Africa, Finland, the Philippines, and the United States, the vaccine efficacy for prevention of World Health Organization (WHO) radiographically defined pneumonia was 27 percent (95% CI 15-36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/48\">",
"     48",
"    </a>",
"    ]. The pooled efficacy for prevention of clinical pneumonia was 6 percent (95% CI 2-9 percent). Findings were similar in children with and without HIV.",
"   </p>",
"   <p>",
"    Data from the Nationwide Inpatient Sample in the United States indicate a 39 percent decline in hospitalizations among children younger than two years for all-cause pneumonia and a 65 percent decline for pneumococcal pneumonia between 1997 to 1999 and 2001 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/58\">",
"     58",
"    </a>",
"    ]. These rates were sustained through 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/59\">",
"     59",
"    </a>",
"    ]. Rates of ambulatory visits for pneumonia in children younger than two years also declined between 1997 to 1999 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/60\">",
"     60",
"    </a>",
"    ], although the rate of ambulatory visits for pneumonia among children aged 1 to 18 years remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/61\">",
"     61",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    There is some evidence to indicate that the absolute number of cases of complicated pneumococcal pneumonia and the proportion of invasive pneumococcal disease caused by pneumonia have increased in the United States after the introduction of PCV7 to the standard childhood immunization schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/59,62-67\">",
"     59,62-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link&amp;anchor=H9889776#H9889776\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\", section on 'Invasive disease caused by non-vaccine serotypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible protection against viral pneumonia &ndash; Two studies from South Africa suggest that pneumococcal conjugate vaccines may reduce the incidence of virus-associated pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a randomized trial of more than 37,000 infants, the 9-valent pneumococcal conjugate vaccine (PCV9) (",
"      <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"       table 1",
"      </a>",
"      ) was associated with a 31 percent reduction in the incidence of pneumonia associated with any of seven respiratory viruses (including influenza, parainfluenza, respiratory syncytial virus, adenovirus) in hospitalized children [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, a cohort of children who had been randomly assigned to receive three doses of PCV9 or placebo was tested for human metapneumovirus when hospitalized for lower respiratory tract infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/69\">",
"       69",
"      </a>",
"      ]. Among children without HIV infection who received three doses of PCV9, the incidence of lower respiratory tract infection (LRTI) and clinical pneumonia due to human metapneumovirus was reduced by 45 percent and 55 percent, respectively. Among HIV-infected children, the incidence of LRTI and clinical pneumonia due to human metapneumovirus was reduced by 53 percent and 65 percent, respectively.",
"      <br/>",
"      <br/>",
"      These observations suggest that bacterial-viral coinfections, particularly coinfection with pneumococcus, play an important role in the pathogenesis of virus-associated pneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized trials, administration of PCV7 has been associated with a modest (6 to 7 percent) relative reduction in the incidence of acute otitis media (AOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/70\">",
"     70",
"    </a>",
"    ]. As a result of the change in nasopharyngeal flora following vaccination, there is a significant reduction in episodes of AOM caused by serotypes cross-reactive with those in the vaccine and a significant increase in episodes caused by other serotypes. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in children: Prevention of recurrence\", section on 'Pneumococcal conjugate vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alternative or abbreviated schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the effectiveness of PCV7 or other pneumococcal conjugate vaccines when administered on an alternative or abbreviated schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]. Alternative schedules generally consist of two doses before six months of age plus a booster dose at &ge;12 months (ie, a &ldquo;2 + 1&rdquo; schedule). In a large randomized trial, a 2 + 1 schedule for PCV10 was 92 percent effective in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/75\">",
"     75",
"    </a>",
"    ]. In two case control studies, a 2 + 1 schedule for PCV7 was 74 to 92 percent effective in preventing IPD caused by vaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of abbreviated schedules (related to vaccine shortages or delayed immunizations) varied depending upon the number and timing of doses and outcome measure (IPD due to any serotype or vaccine serotype) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. A single dose at &lt;3 months of age provided essentially no protection against IPD (any serotype). Various combinations of three or four doses before 16 months that included at least one dose at &ge;12 months provided approximately 90 percent protection against IPD due to any serotype and up to 100 percent protection against IPD due to vaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) recommend immunization with the 13-valent pneumococcal conjugate vaccine (PCV13) for the following groups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1,76\">",
"     1,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All infants and young children aged 2 through 23 months (the first dose can be administered as early as six weeks) (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Routine schedule'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Incompletely immunized children aged 24 through 59 months (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Catch-up schedule'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Healthy children aged 14 through 59 months who completed immunization with the 7-valent pneumococcal conjugate vaccine PCV7 (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Supplemental dose'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Children &lt;72 months of age who are at increased risk of invasive pneumococcal disease (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 3",
"      </a>",
"      ); this includes children who have received the 23-valent pneumococcal conjugate vaccine (PPSV23) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Vaccine schedule'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a single dose of PCV13 may be administered to children aged 6 through 18 years who are at increased risk for invasive pneumococcal disease because of anatomic or functional asplenia (including sickle cell disease), HIV or other immunocompromising condition, chronic renal failure, nephrotic syndrome, cochlear implant, or cerebrospinal fluid leak (regardless of whether they have previously received PCV7",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PPSV23) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. In February 2013, the ACIP voted to recommend PCV13 for such children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/77\">",
"     77",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with the 13-valent pneumococcal conjugate vaccine (PCV13) is contraindicated in children with hypersensitivity to any component of the vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/2,20,21\">",
"     2,20,21",
"    </a>",
"    ]. Immunization of children with moderate or severe illness may be postponed until the child has recovered; minor illness is not a contraindication to immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/2,21\">",
"     2,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DOSE AND ROUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 13-valent pneumococcal conjugate vaccine (PCV13) is administered intramuscularly (IM) as a single 0.5 mL dose [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9697558\">",
"    <span class=\"h1\">",
"     ADMINISTRATION WITH OTHER VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCV13 may be administered concurrently with other routine childhood vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/26,29,78-80\">",
"     26,29,78-80",
"    </a>",
"    ]; it should be injected with a separate syringe at a separate site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VACCINE SCHEDULE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Routine schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine pneumococcal vaccine schedule for healthy and high-risk children in the United States is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy children &ndash; Children &lt;24 months should receive a total of four doses of the 13-valent pneumococcal conjugate vaccine (PCV13): at two, four, six months, and 12 to 15 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"       1",
"      </a>",
"      ]. The first dose can be given as early as six weeks of age. A minimum of four weeks between the three doses is acceptable in children younger than one year. The fourth dose should be given at 12 to 15 months of age but at least eight weeks after the third dose. Preterm infants should receive PCV13 according to their chronologic age [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1,81,82\">",
"       1,81,82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-risk children &ndash; Children at high risk of invasive pneumococcal disease (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 3",
"      </a>",
"      ) who are younger than 24 months should receive PCV13 according to the schedule for healthy children.",
"      <br/>",
"      <br/>",
"      In addition, high-risk children &ge;2 years of age should receive the 23-valent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23) at least eight weeks after they have completed immunization with PCV13 (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H6#H6\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Schedule'",
"      </a>",
"      .) The recommended pneumococcal polysaccharide vaccine schedule for high-risk children depends upon the specific high-risk condition (",
"      <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"       table 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      High-risk children younger than 72 months who completed immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) and PPSV23 should receive a single dose of PCV13 at least eight weeks after the last dose of PCV7 or PPSV23.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transition from PCV7 to PCV13",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCV13 should be used to complete or initiate the series of pneumococcal conjugate vaccines (",
"    <a class=\"graphic graphic_table graphicRef51781 \" href=\"UTD.htm?16/25/16796\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of doses of PCV13 that will be required varies depending upon the number of doses of PCV7 that have been received and whether there are underlying conditions that predispose to pneumococcal disease (",
"    <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Supplemental dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single supplemental dose of PCV13 is recommended for healthy children aged 14 through 59 months who have received four doses of PCV7 or another age-appropriate, complete PCV7 schedule (",
"    <a class=\"graphic graphic_table graphicRef51781 \" href=\"UTD.htm?16/25/16796\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1,83\">",
"     1,83",
"    </a>",
"    ]. The dose should be given at least eight weeks after the last dose of PCV7. The supplemental dose of PCV13 is not required for healthy children who received two or three doses of PCV before age 12 months and at least one dose of PCV13 at &ge;12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"     1",
"    </a>",
"    ]. The importance of the supplemental dose is highlighted by reports of invasive pneumococcal disease caused by one of the six serotypes unique to PCV13 (ie, 1, 3, 5, 6A, 7F, and 19A) among children who were eligible for, but did not receive, PCV13 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children who have medical conditions that increase the risk of pneumococcal disease (",
"    <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"     table 3",
"    </a>",
"    ) and have received four doses of PCV7 or another age-appropriate, complete PCV7 schedule, a single supplemental dose of PCV13 is recommended for children through 71 months of age; this includes children who previously received PPSV23. The supplemental dose of PCV13 should be given at least eight weeks after the last dose of PCV7 or PPSV23.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Catch-up schedule",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy children &ndash; Pneumococcal vaccination of healthy infants and young children who are incompletely vaccinated should occur according to the recommendations in the table (",
"      <a class=\"graphic graphic_table graphicRef51132 \" href=\"UTD.htm?14/1/14365\">",
"       table 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A single dose of PCV13 is recommended for all healthy children aged 24 through 59 months of age who are incompletely immunized [",
"      <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"       1",
"      </a>",
"      ]. The dose should be administered at least eight weeks after the most recent dose of pneumococcal conjugate vaccine.",
"     </li>",
"     <li>",
"      High-risk children &ndash; The recommended pneumococcal vaccine schedule for children 24 through 71 months of age who are at high risk for invasive pneumococcal disease (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 3",
"      </a>",
"      ) depends upon the age of the child, prior exposure to pneumococcal vaccine, and the specific high-risk condition (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 4",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children aged 24 through 71 months with high-risk conditions who received zero, one, or two doses of PCV (PCV7 or PCV13) before age 24 months should receive two doses of PCV13, separated by eight weeks.",
"     </li>",
"     <li>",
"      Children aged 24 through 71 months with high-risk conditions who received three doses of PCV (PCV7 or PCV13) should receive a single dose of PCV13 at least eight weeks after the last dose of PCV13.",
"      <br/>",
"      <br/>",
"      After completion of pneumococcal conjugate vaccine, high-risk children &ge;24 months should receive the 23-valent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23). It should be given at least eight weeks after the last dose of PCV13. High-risk children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia should receive a second dose of PPSV23 five years after the first. A second dose is not recommended for immunocompetent children with cochlear implants or chronic illness (including chronic heart disease, chronic lung disease, diabetes mellitus, and cerebrospinal fluid leaks) (",
"      <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"       table 5",
"      </a>",
"      ) .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Elective splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with PCV13 should be completed at least two weeks before elective splenectomy, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/85\">",
"     85",
"    </a>",
"    ]. PPSV23 can be given &ge;8 weeks after PCV13 (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Pneumococcal vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Immune-compromising therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with PCV13 should be completed at least two weeks before initiation of immune-compromising therapy, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/85\">",
"     85",
"    </a>",
"    ]. PPSV23 can be given &ge;8 weeks after PCV13.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cochlear implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization with PCV13 should be completed at least two weeks before placement of a cochlear implant, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. PPSV23 can be given &ge;8 weeks after PCV13. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=see_link&amp;anchor=H17#H17\">",
"     \"Cochlear implant infections\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have experienced invasive pneumococcal disease should complete the full series of immunization with PCV13",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PPSV23 according to their age and underlying condition. Invasive pneumococcal disease (IPD) elicits serotype-specific antibody, but does not provide protection against the range of serotypes included in PCV13 or PPSV23. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Routine schedule'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Catch-up schedule'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Evaluation of immune function and HIV status may be warranted for children who develop invasive pneumococcal disease with a PCV13 serotype despite having received at least two doses of PCV13 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of the 13-valent pneumococcal conjugate vaccine (PCV13) was assessed in 13 clinical trials, including 4729 healthy infants and toddlers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. The most frequently reported adverse events within seven days of PCV13 included injection site reaction, fever, decreased appetite, irritability, and increased or decreased sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/16\">",
"     16",
"    </a>",
"    ]. Local injection site reactions (of any severity) were reported in 36 to 51 percent of children and fever of 39 to 40&ordm;C in 3 to 4 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the most common reactions following the 7-valent pneumococcal conjugate vaccine (PCV7) in infants were moderate local reactions and fever. Local reactions occurred in 5 to 6 percent of infants, and fever was approximately two times more common than in infants receiving the standard infant vaccines without PCV7 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased rates of febrile seizures have been reported among children, particularly those 12 through 23 months of age, who received PCV13 and the trivalent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (TIV) at the same visit compared with children who received PCV13 and TIV on separate occasions, but the risk is low (approximately 1 in 2000 to 3000) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Because of the greater risks associated with delaying either of these vaccines, the Advisory Committee on Immunization Practices (ACIP) does not recommend administering them at separate visits or deviating from the recommended vaccine schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of reports submitted to the Vaccine Adverse Event Reporting System (VAERS) during the first two years after licensure of PCV7 described minor adverse events that had been observed during clinical trials (eg, local reactions, fever). Serious events were described at a rate similar to that for other vaccines (approximately 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/14/7402/abstract/92\">",
"     92",
"    </a>",
"    ]. Rare but serious adverse events included seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia.",
"   </p>",
"   <p>",
"    VAERS data must be interpreted with caution because many reported events may not be caused by the vaccine. As an example, supplementary follow-up among the first 98 patients with seizures indicated that 80 percent occurred in children who were febrile or in patients with a history of seizures. Symptoms that occurred with subsequent doses of the vaccine, strengthening the possibility of association, included allergic reactions, prolonged crying, fussiness, dyspnea, and GI distress. These, and the rare but serious events described above, warrant continued surveillance.",
"   </p>",
"   <p>",
"    Healthcare providers in the United States should report suspected adverse events to the Vaccine Adverse Event Reporting System (VAERS,",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     vaers.hhs.gov/index",
"    </a>",
"    , telephone number: 1-800-822-7967).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources related to immunization of children younger than six years of age include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/vis/default.htm\">",
"       Vaccine information statement for the 13-valent pneumococcal conjugate vaccine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/\">",
"       The Centers for Disease Control and Prevention",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www2.aap.org/immunization/\">",
"       The American Academy of Pediatrics",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/\">",
"       Immunization Action Coalition",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of pneumococcal conjugate vaccine (PCV) in preventing invasive pneumococcal disease caused by a serotype contained in the vaccine is approximately 80 percent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Efficacy and effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administered according to an alternative or abbreviated schedule, PCV is most effective if at least one dose is administered at &ge;12 months of age. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Alternative or abbreviated schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend universal immunization of infants and children younger than 60 months with the 13-valent pneumococcal conjugate vaccine (PCV13) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also recommend immunization with PCV13 for incompletely immunized children younger than 72 months who are at high risk for invasive pneumococcal disease (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest immunization with a single dose of PCV13 for children aged 6 through 18 years who have sickle cell disease, HIV or other immunocompromising conditions, cochlear implant, or cerebrospinal fluid leak (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first three doses of PCV13 should be administered at two, four, and six months of age; the fourth dose should be administered at 12 to 15 months of age, but at least eight weeks after the third dose. PCV13 is administered intramuscularly (IM) as a single 0.5 mL dose. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Routine schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Dose and route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The schedule for children in high-risk groups also includes the 23-valent polysaccharide vaccine (PPSV23) (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Routine schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Catch-up schedule'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H5#H5\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The catch-up schedule varies depending upon age and number of previous doses (",
"      <a class=\"graphic graphic_table graphicRef51132 \" href=\"UTD.htm?14/1/14365\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Catch-up schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthy children younger than 60 months who completed an immunization series with the 7-valent pneumococcal conjugate vaccine (PCV7) should receive a supplemental dose of PCV13 at least eight weeks after the last dose of PCV7. High-risk children younger than 72 months who completed an immunization series with PCV7 (including those who have received PPSV23) should receive a supplemental dose of PCV13 at least eight weeks after the last dose of PCV7 or PPSV23. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Transition from PCV7 to PCV13'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common reactions following PCV7 and PCV13 in infants are moderate local reactions and fever. Rare but serious adverse events include seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/1\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/2\">",
"      Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/3\">",
"      Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/4\">",
"      Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/5\">",
"      Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/6\">",
"      Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/7\">",
"      Chen YY, Yao SM, Chou CY, et al. Surveillance of invasive Streptococcus pneumoniae in Taiwan, 2002-2003. J Med Microbiol 2006; 55:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/8\">",
"      Berg S, Trollfors B, Persson E, et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006; 38:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/9\">",
"      Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/10\">",
"      Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005; 365:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/11\">",
"      Fraser D, Givon-Lavi N, Bilenko N, Dagan R. A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice. Clin Infect Dis 2001; 33:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/12\">",
"      Puumalainen T, Dagan R, Wuorimaa T, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/13\">",
"      Ispahani P, Slack RC, Donald FE, et al. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Arch Dis Child 2004; 89:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/14\">",
"      Phongsamart W, Srifeungfung S, Dejsirilert S, et al. Serotype distribution and antimicrobial susceptibility of S. pneumoniae causing invasive disease in Thai children younger than 5 years old, 2000-2005. Vaccine 2007; 25:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/15\">",
"      Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Prevnar 13. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm (Accessed on February 02, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/17\">",
"      Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/18\">",
"      Shouval DS, Greenberg D, Givon-Lavi N, et al. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 2009; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/19\">",
"      Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010; 125:429.",
"     </a>",
"    </li>",
"    <li>",
"     Prevnar 13 prescribing information. Wyeth Pharmaceuticals Inc. Philadelphia 2013. file://labeling.pfizer.com/showlabeling.aspx?id=501 (Accessed on February 02, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/21\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/22\">",
"      A pneumococcal conjugate vaccine for infants and children. Med Lett Drugs Ther 2000; 42:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/23\">",
"      Skinner JM, Indrawati L, Cannon J, et al. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011; 29:8870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/24\">",
"      Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. No. 927. 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/26\">",
"      Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010; 125:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/27\">",
"      Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010; 17:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/28\">",
"      Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010; 126:e493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/29\">",
"      Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012; 31:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/30\">",
"      O'Brien KL, Moisi J, Moulton LH, et al. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 2007; 196:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/31\">",
"      Dagan R, Givon-Lavi N, Greenberg D, et al. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010; 201:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/32\">",
"      Rodenburg GD, van Gils EJ, Veenhoven RH, et al. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J Pediatr 2011; 159:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/33\">",
"      van den Biggelaar AH, Pomat WS, Phuanukoonnon S, et al. Effect of early carriage of Streptococcus pneumoniae on the development of pneumococcal protein-specific cellular immune responses in infancy. Pediatr Infect Dis J 2012; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/34\">",
"      Rodenburg GD, van Gils EJ, Veenhoven RH, et al. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine 2010; 28:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/35\">",
"      Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr Infect Dis J 2010; 29:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/36\">",
"      Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/37\">",
"      O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/38\">",
"      Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/39\">",
"      Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/40\">",
"      Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009; 123:e1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/41\">",
"      Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/43\">",
"      Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/45\">",
"      Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/46\">",
"      Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/47\">",
"      Rosen JB, Thomas AR, Lexau CA, et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis 2011; 53:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/48\">",
"      Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009; :CD004977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/49\">",
"      Ladhani SN, Andrews NJ, Waight P, et al. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales. Clin Infect Dis 2013; 56:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/50\">",
"      Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/51\">",
"      Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/52\">",
"      Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/53\">",
"      Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/54\">",
"      Laupland KB, Gregson DB, Vanderkooi OG, et al. The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006. Pediatr Infect Dis J 2009; 28:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/56\">",
"      Kaplan SL, Barson WJ, Lin PL, et al. Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J 2013; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     Moore M, Link-Gelles R, Farley MM, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S, 2010-11 (abstract). ID Week, San Francisco, CA 2013. file://idsa.confex.com/idsa/2012/webprogram/Paper36569.html (Accessed on February 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/58\">",
"      Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/59\">",
"      Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis 2010; 50:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/60\">",
"      Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007; 161:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/61\">",
"      Kronman MP, Hersh AL, Feng R, et al. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994-2007. Pediatrics 2011; 127:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/62\">",
"      Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/63\">",
"      Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate pneumococcal vaccine in arkansas. Pediatr Infect Dis J 2004; 23:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/64\">",
"      Byington CL, Korgenski K, Daly J, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006; 25:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/65\">",
"      Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/66\">",
"      Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010; 48:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/67\">",
"      Lee GE, Lorch SA, Sheffler-Collins S, et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics 2010; 126:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/68\">",
"      Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/69\">",
"      Madhi SA, Ludewick H, Kuwanda L, et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006; 193:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/70\">",
"      Jansen AG, Hak E, Veenhoven RH, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2009; :CD001480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/71\">",
"      Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/72\">",
"      Mahon BE, Hsu K, Karumuri S, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 2006; 24:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/73\">",
"      Vestrheim DF, L&oslash;voll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26:3277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/74\">",
"      Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J 2010; 29:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/75\">",
"      Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/76\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126:186.",
"     </a>",
"    </li>",
"    <li>",
"     Medscape Medical News. CDC panel endorses PCV13 use in immunocompromised children. February 20, 2013. file://www.medscape.com/viewarticle/779664?src=emailthis (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/78\">",
"      Gimenez-Sanchez F, Kieninger DM, Kueper K, et al. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:6042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/79\">",
"      Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics 2011; 128:e1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/80\">",
"      Bryant KA, Gurtman A, Girgenti D, et al. Antibody Responses to Routine Pediatric Vaccines Administered With 13-valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J 2013; 32:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/81\">",
"      R&uuml;ckinger S, van der Linden M, von Kries R. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infect Dis 2010; 10:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/82\">",
"      D'Angio CT, Heyne RJ, O'Shea TM, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J 2010; 29:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/83\">",
"      Frenck R Jr, Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/84\">",
"      Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged &le;59 months---selected U.S. regions, 2010--2011. MMWR Morb Mortal Wkly Rep 2011; 60:1477.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/86\">",
"      Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/87\">",
"      Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000; 106:367.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Febrile seizures associated with TIV &amp; PCV13. file://www.cdc.gov/vaccines/pubs/vis/tiv-pcv-note.htm (Accessed on September 01, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Update on febrile seizures in children following vaccination with influenza vaccines and pneumococcal vaccines file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/90\">",
"      Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012; 30:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/91\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/14/7402/abstract/92\">",
"      Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6053 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7402=[""].join("\n");
var outline_f7_14_7402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONJUGATE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      13-valent vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      7-valent vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMMUNOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFICACY AND EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alternative or abbreviated schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DOSE AND ROUTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9697558\">",
"      ADMINISTRATION WITH OTHER VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VACCINE SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Routine schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transition from PCV7 to PCV13",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Supplemental dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Elective splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Immune-compromising therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cochlear implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6053|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/61/24543\" title=\"figure 1\">",
"      Potential PCV coverage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/37/32350\" title=\"figure 2\">",
"      Proportion IPD due to vaccine serotypes in children 0 to 5 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/26/10658\" title=\"figure 3\">",
"      Rates of IPD after PCV7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/43/701\" title=\"table 2\">",
"      Comparison of pneumococcal conjugate and polysaccharide vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/13/6364\" title=\"table 3\">",
"      High risk conditions for invasive pneumococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 4\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24523\" title=\"table 5\">",
"      PPSV23 schedule for high-risk children older than two years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/25/16796\" title=\"table 6\">",
"      PCV7 to PCV13 transition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/1/14365\" title=\"table 7\">",
"      Catch up schedule PCV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=related_link\">",
"      Cochlear implant infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=related_link\">",
"      Microbiology and pathogenesis of Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_14_7403="Benzodiazepines chronic pain";
var content_f7_14_7403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benzodiazepines for chronic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route of administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam (Valium)",
"       </td>",
"       <td>",
"        PO/IM/PR",
"       </td>",
"       <td>",
"        2.5 mg Q 3 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorazepam (Ativan)",
"       </td>",
"       <td>",
"        PO/IV/IM",
"       </td>",
"       <td>",
"        0.5 to 2 mg Q 3 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam (Versed)",
"       </td>",
"       <td>",
"        PO/IV/SC (can be continuous infusion)",
"       </td>",
"       <td>",
"        1 to 3 mg Q 1 to 3 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonazepam (Klonopin)",
"       </td>",
"       <td>",
"        PO",
"       </td>",
"       <td>",
"        Up to 1.5 mg/day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7403=[""].join("\n");
var outline_f7_14_7403=null;
var title_f7_14_7404="Classification NCPH";
var content_f7_14_7404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of noncirrhotic portal hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Prehepatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Portal vein thrombosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Splenic vein thombosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Splanchnic arteriovenous fistula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Splenomegaly (lymphoma, Gaucher's disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Intrahepatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Presinusoidal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Schistosomiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Idiopathic portal hypertension/Noncirrhotic portal fibrosis/Hepatoportal sclerosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Primary biliary cirrhosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Congenital hepatic fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sclerosing cholangitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hepatic arteriopetal fistula",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Sinusoidal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Arsenic poisoning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vinyl chloride toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vitamin A toxicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nodular regenerative hyperplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Postsinusoidal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sinusoidal obstruction syndrome (Veno-occlusive disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Budd-Chiari syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Posthepatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IVC obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiac disease (constrictive pericarditis, restrictive cardiomyopathy)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7404=[""].join("\n");
var outline_f7_14_7404=null;
var title_f7_14_7405="Commonly abused drugs PI";
var content_f7_14_7405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly abused prescription drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        US brand names",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prescribed to treat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codeine and guaifenesin",
"       </td>",
"       <td>",
"        Robitussin AC&reg;",
"       </td>",
"       <td rowspan=\"2\">",
"        Cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocodone and homatropine",
"       </td>",
"       <td>",
"        <p>",
"         Hycodan&reg;",
"        </p>",
"        <p>",
"         Hydromet&reg;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Buprenorphine",
"       </td>",
"       <td>",
"        <p>",
"         Buprenex&reg;",
"        </p>",
"        <p>",
"         Butrans&reg;",
"        </p>",
"       </td>",
"       <td rowspan=\"10\">",
"        Severe pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codeine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codeine and acetaminophen",
"       </td>",
"       <td>",
"        Tylenol&reg; with codeine No. 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocodone and acetaminophen",
"       </td>",
"       <td>",
"        <p>",
"         Vicodin&reg;",
"        </p>",
"        <p>",
"         Lorcet&reg;",
"        </p>",
"        <p>",
"         Lortab&reg;",
"        </p>",
"        <p>",
"         Others",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydromorphone",
"       </td>",
"       <td>",
"        <p>",
"         Dilaudid&reg;",
"        </p>",
"        <p>",
"         Exalgo&trade;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        Dolophine&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"       </td>",
"       <td>",
"        <p>",
"         Avinza&reg;",
"        </p>",
"        <p>",
"         Kadian&reg;",
"        </p>",
"        <p>",
"         Oramorph SR&reg;",
"        </p>",
"        <p>",
"         MS Contin&reg;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        <p>",
"         Oxecta&trade;",
"        </p>",
"        <p>",
"         Oxycontin&reg;",
"        </p>",
"        <p>",
"         Roxicodone&reg;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone and acetaminophen",
"       </td>",
"       <td>",
"        <p>",
"         Endocet&reg;",
"        </p>",
"        <p>",
"         Percocet&reg;",
"        </p>",
"        <p>",
"         Roxicet&reg;",
"        </p>",
"        <p>",
"         Tylox&reg;",
"        </p>",
"        <p>",
"         Others",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxymorphone",
"       </td>",
"       <td>",
"        Opana&reg;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Amphetamine and dextroamphetamine",
"       </td>",
"       <td>",
"        Adderall XR&reg;",
"       </td>",
"       <td rowspan=\"3\">",
"        Attention deficit hyperactivity disorder (ADHD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methamphetamine",
"       </td>",
"       <td>",
"        Desoxyn&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylphenidate",
"       </td>",
"       <td>",
"        <p>",
"         Ritalin&reg;",
"        </p>",
"        <p>",
"         Concerta&reg;",
"        </p>",
"        <p>",
"         Daytrana&reg;",
"        </p>",
"        <p>",
"         Others",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Alprazolam",
"       </td>",
"       <td>",
"        Xanax&reg;",
"       </td>",
"       <td rowspan=\"4\">",
"        Anxiety and sleep problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam",
"       </td>",
"       <td>",
"        Valium&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonazepam",
"       </td>",
"       <td>",
"        Klonopin&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lorazepam",
"       </td>",
"       <td>",
"        Ativan&reg;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Carisoprodol",
"       </td>",
"       <td>",
"        Soma&reg;",
"       </td>",
"       <td>",
"        Muscle spasms, back pain",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Prescription drugs that are abused to increase muscle growth and to help athletes do better in sports are not covered here. Please see UpToDate article \"Use of androgens and other hormones to enhance athletic performance\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7405=[""].join("\n");
var outline_f7_14_7405=null;
var title_f7_14_7406="Zoster and PHN by age";
var content_f7_14_7406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Rates* of zoster and postherpetic neuralgia (PHN)&bull;, by age - United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per 1000 person-years.",
"     <br>",
"      &bull; Defined as &ge;30 days of pain.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7406=[""].join("\n");
var outline_f7_14_7406=null;
var title_f7_14_7407="Calcified gallstones KUB";
var content_f7_14_7407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcified gallstones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A plain abdominal x-ray showing calcified gallstones in the gallbladder (GB), cystic duct (CD) and common bile duct (CBD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_14_7407=[""].join("\n");
var outline_f7_14_7407=null;
